26.03.

2025
11:00 - 12:00 Type: Industry Satellite Symposium Room N02
Title: MSD - Pioneering thoracic oncology: Advancements, challenges, and
integrated care pathways
Moderation: Virginie Westeel, France

11:00 - 11:05 Welcome and introduction

Virginie Westeel, CHRU Besancon - Hopital Jean Minjoz, Besancon, France

11:05 - 11:35 Evolving frontiers in early-stage NSCLC treatment: Exploring novel therapeutic pathways
and clinical outcomes

Solange Peters1, Jan Von Der Thüsen2, Olaf Mercier3, Virginie Westeel4, 1Centre Hospitalier
Universitaire Vaudois, Lausanne University, Lausanne, Switzerland, 2Erasmus MC - Erasmus
University Rotterdam, Rotterdam, Netherlands, 3Centre Chirurgical Marie Lannelongue, Le
Plessis-Robinson, France, 4CHRU Besancon - Hopital Jean Minjoz, Besancon, France

11:35 - 11:55 10 years of immunotherapy: What have we learned? Perspectives and practical
approaches in mNSCLC management

Virginie Westeel1, Solange Peters2, Olaf Mercier3, 1CHRU Besancon - Hopital Jean Minjoz,
Besancon, France, 2Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne,
Switzerland, 3Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, France

11:55 - 12:00 Closing remarks

Virginie Westeel, CHRU Besancon - Hopital Jean Minjoz, Besancon, France

11:00 - 12:00 Type: Industry Satellite Symposium Room N03

Title: AstraZeneca & Thermo Fisher Scientific - The next frontier in NSCLC
diagnostics: Integrating emerging biomarkers into clinical practice
Moderation: Philip Jermann, Switzerland

11:00 - 11:05 Welcome and Introduction

Philip Jermann, Life Technologies Europe B.V. - Thermo Fisher Scientific, Zug, Switzerland

11:05 - 11:20 Emerging biomarkers: shaping the future of NSCLC testing and clinical integration
Natasha Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto,
Canada

11:20 - 11:35 Real-world insights into the analytical performance of next generation sequencing for
HER2 mutation detection
Fernando Schmitt, IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do
Porto, Porto, Portugal

11:35 - 11:55 Q&A and panel discussion

11:55 - 12:00 Closing remarks

Last update: 05-03-2025 10:21:13am

 12:20 - 13:20 Type: ESMO Colloquium Room N02
Title: ESMO Colloquium supported by Eli Lilly and Company - Optimising
diagnosis and management of patients with oncogene-addicted localised
non-small cell lung cancer
Moderation: Pilar Garrido Lopez, Spain; Mariana Brandao, Belgium

12:20 - 12:23 Welcome and introduction

Pilar Garrido Lopez, Hospital Universitario Ramón y Cajal, Madrid, Spain

12:23 - 12:35 Clinical case of localised NSCLC relapsing with oncogene-addicted metastases and
analysis of real-world biomarker testing strategies
Mariana Brandao, Institut Jules Bordet, Anderlecht, Belgium

12:35 - 12:47 How to optimise the science and workflows for biomarker testing in localised NSCLC:
Tissue and plasma
Frederique Penault-Llorca, Centre Jean Perrin, Clermont-Ferrand, France

12:47 - 12:59 State-of-the-art biomarker-driven management of patients with oncogene-addicted

localised NSCLC
Pilar Garrido Lopez, Hospital Universitario Ramón y Cajal, Madrid, Spain

12:59 - 13:11 Ongoing clinical research activity for patients with localised oncogene-addicted NSCLC
Fabrice Barlesi, Gustave Roussy - Cancer Campus, Villejuif, France

13:11 - 13:18 Q&A

13:18 - 13:20 Concluding remarks

Mariana Brandao, Institut Jules Bordet, Anderlecht, Belgium

12:20 - 13:20 Type: Industry Satellite Symposium Room N03

Title: AbbVie Inc. - Where do you c-Met in lung cancer? Antibody-drug
conjugates in NSCLC
Moderation: Antonio Passaro, Italy; Enriqueta Felip, Spain

12:20 - 12:30 Welcome and introduction

Antonio Passaro, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy

12:30 - 12:45 All MET aberrations are not created equal

Antonio Passaro, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy

12:45 - 13:05 Exploring antibody-drug conjugates targeting c-Met

Enriqueta Felip, Department of Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona,
Spain

13:05 - 13:20 Panel discussion, Q&A

Last update: 05-03-2025 10:21:13am

 13:20 - 13:50 Type: Coffee break Foyer
Title: Welcome reception

13:50 - 14:30 Type: Keynote lecture Room South Paris

Title: Opening session and Heine H. Hansen Award

13:50 - 14:00 Welcome to the European Lung Cancer Congress 2025 by the Scientific Co-Chairs

14:00 - 14:05 Introduction to the Heine H. Hansen Award 2025

14:05 - 14:30 Heine H. Hansen Award 2025 - Keynote lecture

Keith Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, United Kingdom

14:45 - 16:15 Type: Educational session Room South Paris

Title: Novel immunotherapies beyond the PD1 pathway
Moderation: Solange Peters, Switzerland; Natasha Leighl, Canada

14:45 - 15:05 New actionable immune checkpoints

Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for
Lung Research, Grosshansdorf, Germany

15:05 - 15:25 Vaccines: How and when?

Melissa Johnson, Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of
America

15:25 - 15:45 Bispecifics and T cell engagers: Fighting against immune desert
Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne,
Switzerland

15:45 - 16:05 Cellular therapies: The future?

Ben Creelan, H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa,
United States of America

16:05 - 16:15 Q&A and discussion

14:45 - 16:15 Type: Educational session Room N02

Title: What did we always wanted to know from each other in thoracic
neoplasms
Moderation: Maria Rosario Garcia Campelo, Spain; Pei Li Stephanie Saw, Singapore

14:45 - 15:05 What I as thoracic surgeon always wanted to know from my pathologist
David A. Waller, Spire Leicester Hospital, Leicester, United Kingdom

15:05 - 15:25 Come together: The value of the frozen section laboratory and what the pathologist needs
to know from the surgeon
Anja Roden, Mayo Clinic - Rochester, Rochester, United States of America

Last update: 05-03-2025 10:21:13am

 15:25 - 15:45 What I as radiation oncologist always wanted to know from my pathologist and my
surgeon
Annemarie Shepherd, University of Washington, Seattle, United States of America

15:45 - 16:05 What I as medical oncologist always wanted to know from my pathologist and my surgeon
Maria Rosario Garcia Campelo, CHUAC - Complejo Hospitalario Universitario A Coruña, A
Coruña, Spain

16:05 - 16:15 Q&A and discussion

15:15 - 16:15 Type: Controversy session Room N03

Title: Invasive mediastinal re-staging after Chemo-IO neoadjuvant therapy:
Pros and cons
Moderation: Paul van Schil, Belgium

15:15 - 15:25 Introduction and first vote

Paul Van Schil, UZA - University Hospital Antwerp, Edegem, Belgium

15:25 - 15:45 Pros

Leah Backhus, Stanford University, Stanford, United States of America

15:45 - 16:05 Cons

Nan Wu, Peking University Cancer Hospital and Institute, Beijing, China

16:05 - 16:15 Second vote and conclusions/discussion

Paul Van Schil, UZA - University Hospital Antwerp, Edegem, Belgium

16:00 - 16:45 Type: Young Oncologists session Foyer

Title: YO Mentorship session - From national to international oncology
societies: Tips from young oncologists to young oncologists about career
advancement options in thoracic oncology
Moderation: Elene Mariamidze, Georgia; Myrto Moutafi, Greece; Hongcheng Zhu, China

16:00 - 16:45 Round table dicussion

Mariana Brandao1, Roberto Ferrara2, 1Institut Jules Bordet, Anderlecht, Belgium, 2UniSR -
Università Vita e Salute San Raffaele Milano, Milan, Italy

16:15 - 16:45 Type: Coffee break Foyer

Title: Coffee break

16:45 - 18:15 Type: Educational session Room N02

Title: Innovation in actionable genomic alterations (AGA)
Moderation: Sanjay Popat, United Kingdom; Antonio Passaro, Italy

Last update: 05-03-2025 10:21:13am

 16:45 - 17:05 Emerging therapeutics for intracranial metastases in oncogene-driven non-small cell lung
cancer
Xiuning Le, Department of Thoracic Head and Neck Medical Oncology, The University of Texas
MD Anderson Cancer Center, Houston, United States of America

17:05 - 17:25 EGFR mutations: Beyond TKIs - integrating bipsecifics and ADCs
Sanjay Popat, Lung Unit, Royal Marsden Hospital, London, United Kingdom

17:25 - 17:45 ALK Fusions: Where do we go after lorlatinib?

Geoffrey Liu, UHN - University Health Network - Princess Margaret Cancer Center, Toronto,
Canada

17:45 - 18:05 K-Ras mutations: Novel mechanisms for drugging the undruggable
Chiara Ambrogio, Università degli Studi di Torino - Centro Interdipartimentale di Ricerca per le
Biotecnologie, Torino, Italy

18:05 - 18:15 Q&A and discussion

16:45 - 18:15 Type: Proffered Paper session Room South Paris

Title: Proffered Paper session 1
Moderation: Maurice Perol, France; Natasha Leighl, Canada

16:45 - 16:57 4O - Amivantamab Plus Lazertinib vs Osimertinib in First-line (1L) EGFR-mutant (EGFRm)
Advanced NSCLC: Final Overall Survival (OS) from the Phase 3 MARIPOSA Study
James Chih-Hsin Yang, National Taiwan University, Taipei City, Taiwan

16:57 - 17:04 Invited Discussant 4O

Maurice Perol, Centre Léon Bérard, Lyon, France

17:04 - 17:14 Q&A and discussion

17:14 - 17:26 2O - SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm
advanced NSCLC and MET overexpression (OverExp) and/or amplification (Amp) following
progressive disease (PD) on osi
Myung-Ju Ahn, Samsung Medical Center - Sungkyunkwan University School of Medicine, Seoul,
Republic of Korea

17:26 - 17:38 3O - Phase I/II SOHO-01 study of BAY 2927088 in patients with previously treated HER2-
mutant NSCLC: Safety and efficacy results from 2 expansion cohorts
Nicolas Girard, Institut Curie, Paris, France

17:38 - 17:50 1O - Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-
mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L)
osi: ORCHARD
Xiuning Le, Department of Thoracic Head and Neck Medical Oncology, The University of Texas
MD Anderson Cancer Center, Houston, United States of America

Last update: 05-03-2025 10:21:13am

 17:50 - 18:05 Invited Discussant 2O, 3O and 1O
Pei Li Stephanie Saw, NCCS - National Cancer Centre Singapore, Singapore, Singapore

18:05 - 18:15 Q&A and discussion

16:45 - 18:15 Type: Educational session Room N03

Title: Lung cancer screening
Moderation: Joachim Aerts, Netherlands; Laura Mezquita, Spain

16:45 - 17:05 Lung cancer screening: How to select the target population
Witold Rzyman, Medical University of Gdansk, Gdansk, Poland

17:05 - 17:25 Lung cancer screening: Nodule detection on regular care CT scans
Joachim Aerts, Erasmus MC - University Medical Center, Rotterdam, Netherlands

17:25 - 17:45 Lung cancer screening in never smokers

Yeun-Chung Chang, National Taiwan University Hospital and National Taiwan University College
of Medicine, Taipei, Taiwan, Taiwan

17:45 - 18:05 Disparities in lung cancer screening

Phil Crosbie, The University of Manchester, Manchester, United Kingdom

18:05 - 18:15 Q&A and discussion

Last update: 05-03-2025 10:21:13am

 27.03.2025
08:15 - 09:45 Type: Educational session Room South Paris
Title: Above RECIST: A new role for MRD and cfDNA in tumour assessment
Moderation: Thierry Berghmans, Belgium; Catherine Alix-Panabieres, France

08:15 - 08:35 Liquid biopsy: Principles and pitfalls for the clinician
Catherine Alix-Panabieres, Institut Universitaire de Recherche Clinique, Paris, France

08:35 - 08:55 cfDNA for targeted therapies: Current position and future developments
Thomas John, Peter MacCallum Cancer Centre, Melbourne, Australia

08:55 - 09:15 Has MRD detection a role for guiding treatment adaptation in non-oncogene addicted
early NSCLC?
Atocha Romero, Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De
Hierro Majadahonda, Majadahonda, Spain

09:15 - 09:35 Is liquid biopsy a tool for detecting early relapse in lung cancer patients?
Heather Wakelee, Standford University, Stanford, United States of America

09:35 - 09:45 Q&A and discussion

08:15 - 09:45 Type: Educational session Room N02

Title: Thymic epithelial tumours: What is new in a multidisciplinary
approach
Moderation: Enrico Ruffini, Italy; Anja Roden, United States of America

08:15 - 08:35 The TNM stage classification of thymic tumors replacing Masaoka stage system: Old habits
die hard
Edith Marom, Chaim Sheba Medical Center, Ramat Gan, Israel

08:35 - 08:55 Thymoma and thymic carcinoma: Different surgical management strategies?
Enrico Ruffini, Università di Torino, Torino, Italy

08:55 - 09:15 Update on systemic therapy in thymic epithelial tumors

Nicolas Girard, Institut Curie, Paris, France

09:15 - 09:35 Postoperative radiotherapy in thymic tumors: New indications after the TNM stage
classification
Andreas Rimner, Universitätsklinikum Freiburg - Klinik für Strahlenheilkunde, Freiburg im
Breisgau, Germany

09:35 - 09:45 Q&A and discussion

Last update: 05-03-2025 10:21:13am

 08:45 - 09:45 Type: Multidisciplinary Tumour Board Room N03
Title: Borderline resectable NSCLC: What is the best approach?
Moderation: Mariano Provencio Pulla, Spain; Isabelle Schmitt-Opitz, Switzerland

08:45 - 08:55 Definiton of "borderline resectability" and surgical approach

Paula Ugalde, Harvard Medical School, Boston, United States of America

08:55 - 09:10 The role of radiotherapy

Matthias Guckenberger, USZ - University Hospital Zürich, Zurich, Switzerland

09:10 - 09:25 The effect of systemic therapy

Mariano Provencio Pulla, University Hospital Puerta de Hierro Majadahonda, Majadahonda,
Spain

09:25 - 09:45 Q&A and discussion

09:45 - 10:15 Type: Coffee break Foyer

Title: Coffee break

10:15 - 11:45 Type: Educational session Room N02

Title: Biology and novel agents in SCLC
Moderation: Kersti Oselin, Estonia; Caicun Zhou, China

10:15 - 10:35 Recent developments in genomics and translational research of SCLC

Julie George, University Hospital Cologne, Köln, Germany

10:35 - 10:55 Potential mechanisms of treatment resistance: Why many promising compounds have
failed
Carminia Della Corte, Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy

10:55 - 11:15 Role of radiation in the treatment of SCLC and radiosensitizers

Bjorn Gronberg, NTNU - Norwegian University of Science and Technology, Trondheim, Norway

11:15 - 11:35 Novel therapeutic classes and targetable pathways: What's next in the clinic?
Kersti Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn,
Estonia

11:35 - 11:45 Q&A and discussion

10:15 - 11:45 Type: Educational session Room South Paris

Title: Biomarker testing: Sharing experiences among the countries
Moderation: Umberto Malapelle, Italy; Noemi Reguart, Spain

10:15 - 10:35 To single gene testing to CGP in lung cancer

Umberto Malapelle, Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia,
Napoli, Italy

Last update: 05-03-2025 10:21:13am

 10:35 - 10:55 Availability and accessibility of biomolecular technologies in oncology in Europe
Arnaud Bayle, Institut Gustave Roussy, Villejuif, France

10:55 - 11:15 Availability and accessibility of biomolecular technologies in oncology in MENA region
Ola Khorshid, NCI - National Cancer Institute, Cairo, Egypt

11:15 - 11:35 Availability and accessibility of biomolecular technologies in oncology in Asia

Tetsuya Mitsudomi, Kindai University - Faculty of Medicine, Osaka, Japan

11:35 - 11:45 Q&A and discussion

10:45 - 11:45 Type: Controversy session Room N03

Title: Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the
time for TKI combinations arrived?
Moderation: Myung-Ju Ahn, Republic of Korea

10:45 - 10:55 Introduction and first vote

Myung-Ju Ahn, Samsung Medical Center - Sungkyunkwan University School of Medicine, Seoul,
Republic of Korea

10:55 - 11:15 Osimertinib monotherapy remains our current standard of care

Zofia Piotrowska, MGH - Massachusetts General Hospital, Boston, United States of America

11:15 - 11:35 The time for TKI combinations is now

Antonio Passaro, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy

11:35 - 11:45 Second vote and conclusions/discussion

Myung-Ju Ahn, Samsung Medical Center - Sungkyunkwan University School of Medicine, Seoul,
Republic of Korea

12:00 - 13:00 Type: Industry Satellite Symposium Room N03

Title: Regeneron Pharmaceuticals, Inc. - A new era: Reshaping the role of
immunotherapy in the treatment of NSCLC
Moderation: Nicolas Girard, France

12:00 - 12:05 Introduction

Nicolas Girard, Institut Curie, Paris, France

12:05 - 12:20 First things first: Identifying novel targets for non-oncogene-driven NSCLC
Nicolas Girard, Institut Curie, Paris, France

12:20 - 12:35 Leveraging the therapeutic timeline: Sequencing of ICIs and chemotherapy to derive
treatment benefit after initial progression
Andrea Ardizzoni, University of Bologna - Alma Mater Studiorum, Bologna, Italy

Last update: 05-03-2025 10:21:13am

 12:35 - 12:50 Time is ticking: A look at the prevailing unmet needs for second-line strategies in non-
oncogene-driven NCSLC
Alfredo Addeo, HUG - Hopitaux Universitaires de Geneve, Geneva, Switzerland

12:50 - 13:00 Closure

Nicolas Girard, Institut Curie, Paris, France

12:00 - 13:00 Type: Industry Satellite Symposium Room N02

Title: AstraZeneca - Choosing the right treatment for patients with EGFRm
NSCLC: Current standards of care and future opportunities
Moderation: Sanjay Popat, United Kingdom

12:00 - 12:03 Welcome

Sanjay Popat, Lung Unit, Royal Marsden Hospital, London, United Kingdom

12:03 - 12:10 Current standards of care for stage III unresectable EGFRm NSCLC
Sanjay Popat, Lung Unit, Royal Marsden Hospital, London, United Kingdom

12:10 - 12:25 First-line treatment of metastatic EGFRm NSCLC: Balancing efficacy and safety
Zofia Piotrowska, MGH - Massachusetts General Hospital, Boston, United States of America

12:25 - 12:37 Discussion and Q&A

12:37 - 12:47 Post-progression in metastatic EGFRm NSCLC: Current and future options
Jurgen Wolf, Universitätsklinikum Köln (AöR), Cologne, Germany

12:47 - 12:57 Discussion and Q&A

12:57 - 13:00 Conclusions

Sanjay Popat, Lung Unit, Royal Marsden Hospital, London, United Kingdom

13:00 - 13:45 Type: Young Oncologists session Foyer

Title: YO Vesalius talk - Mending the gender gap in oncology: How to
manage our practice for equitable opportunities
Moderation: Elene Mariamidze, Georgia; Myrto Moutafi, Greece; Hongcheng Zhu, China

13:00 - 13:45 Panel discussion

Sanjay Popat1, Solange Peters2, Pilar Garrido Lopez 3, Corinne Faivre-Finn4, 1Lung Unit, Royal
Marsden Hospital, London, United Kingdom, 2Centre Hospitalier Universitaire Vaudois, Lausanne
University, Lausanne, Switzerland, 3Hospital Universitario Ramón y Cajal, Madrid, Spain, 4The
Christie NHS Foundation Trust, Manchester, United Kingdom

Last update: 05-03-2025 10:21:13am

 14:00 - 15:30 Type: Educational session Room South Paris
Title: Advances in oligometastatic disease
Moderation: Antonin Levy, France; Corinne Faivre-Finn, United Kingdom

14:00 - 14:20 Refining the definition of oligometastatic disease: Integrating biological insights
Ashley Horne, The Christie NHS Foundation Trust, Manchester, United Kingdom

14:20 - 14:40 Standard of care treatments for oligometastatic disease

Fiona Mcdonald, The Royal Marsden Hospital - Chelsea, London, United Kingdom

14:40 - 15:00 Breakthroughs in oligometastatic disease management

Antonin Levy, Institut Gustave Roussy, Villejuif, France

15:00 - 15:20 What matters to patients with oligometastatic disease

Jill Feldman, EGFR Resisters, Deerfield, United States of America

15:20 - 15:30 Q&A and discussion

14:00 - 15:30 Type: Educational session Room N02

Title: The role of AI in lung cancer
Moderation: Arsela Prelaj, Italy; Andreas Rimner, Germany

14:00 - 14:20 AI in lung cancer pathology

Jakob Nikolas Kather, Technische Universität Dresden - Carl Gustav Carus Faculty of Medicine,
Dresden, Germany

14:20 - 14:40 AI in lung cancer imaging

Florian Fintelmann, Harvard University, Cambridge, United States of America

14:40 - 15:00 AI in response assessment

Arsela Prelaj, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

15:00 - 15:20 AI in radiation treatment planning

Joseph Deasy, Memorial Sloan-Kettering Cancer Center, New York, United States of America

15:20 - 15:30 Q&A and discussion

14:30 - 15:30 Type: Controversy session Room N03

Title: Duration of adjuvant treatment: Is “as long as possible” the key?
Moderation: Heather Wakelee, United States of America

14:30 - 14:40 Introduction and first vote

Heather Wakelee, Standford University, Stanford, United States of America

Last update: 05-03-2025 10:21:13am

 14:40 - 15:00 PRO: As long as possible
Hye Ryun Kim, Yonsei Cancer Center Yonsei University, Seoul, Republic of Korea

15:00 - 15:20 CONTRA: Limited duration

Rafal Dziadziuszko, Medical University of Gdansk, Gdansk, Poland

15:20 - 15:30 Second vote and conclusions/discussion

Heather Wakelee, Standford University, Stanford, United States of America

15:30 - 16:00 Type: Coffee break Foyer

Title: Coffee break

16:00 - 17:05 Type: Mini Oral session Room South Paris

Title: Mini Oral session 1
Moderation: Adrianus Johannes De Langen, Netherlands; Julien Mazieres, France

16:00 - 16:05 5MO - First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with
advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) and PD-L1
_50% from the phase 2 portion of KRYSTAL-7
Marina Garassino, University of Chicago Department of Medicine - Section of
Hematology/Oncology, Chicago, United States of America

16:05 - 16:10 6MO - Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell
lung cancer (NSCLC)
Salman Punekar, New York University Medical Center, New York, United States of America

16:10 - 16:15 LBA1 - First-line (1L) fulzerasib + cetuximab in KRAS G12Cm advanced NSCLC: updated
efficacy and safety from KROCUS study
Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

16:15 - 16:25 Invited Discussant 5MO, 6MO and LBA1

Adrianus Johannes De Langen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek
Hospital, Amsterdam, Netherlands

16:25 - 16:30 7MO - A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs
pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or
metastatic non-small cell lung cancer (NSCLC)
Ernest Nadal, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet
de Llobregat, Spain

16:30 - 16:35 8MO - Subcutaneous (SC) Versus Intravenous (IV) Pembrolizumab (Pembro) Plus
Chemotherapy (CT) in Metastatic Non-Small Cell Lung Cancer (mNSCLC): Phase 3 MK-
3475A-D77 Trial
Enriqueta Felip, Department of Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona,
Spain

Last update: 05-03-2025 10:21:13am

 16:35 - 16:40 Invited Discussant 7MO and 8MO
Rosalyn Juergens, Hamilton, Canada

16:40 - 16:45 LBA2 - Taletrectinib vs crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer
(NSCLC): A matching-adjusted indirect comparison (MAIC)
Misako Nagasaka, UCI Health Chao Family Comprehensive Cancer Center, Orange, United States
of America

16:45 - 16:50 9MO - Amivantamab, lazertinib and bevacizumab in EGFR-mutant advanced NSCLC with
acquired resistance to 3rd generation EGFR-TKI - Final results from the phase II ETOP
AMAZE-lung trial
Ross Soo, NCIS - National University Cancer Institute Singapore, Singapore, Singapore

16:50 - 16:55 10MO - Preventing Moderate to Severe Dermatologic Adverse Events in First-line EGFR-
mutant Advanced NSCLC Treated with Amivantamab Plus Lazertinib: Early Success of the
COCOON Trial
Nicolas Girard, Institut Curie, Paris, France

16:55 - 17:05 Invited Discussant LBA2, 9MO and 10MO

Julien Mazieres, Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, France

16:00 - 17:00 Type: Multidisciplinary Tumour Board Room N02

Title: How to manage locally advanced NSCLC with poor lung function
Moderation: JUNKO TANIZAKI, Japan; Eric Lim, United Kingdom

16:00 - 16:15 Case presentation and the medical oncologist perspective

Junko Tanizaki, Kindai University - Faculty of Medicine, Osaka, Japan

16:15 - 16:30 Integrating surgery with immunotherapy advances

Nasser Altorki, NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, United
States of America

16:30 - 16:45 The role of radiation therapy in the era of immunotherapy

Corinne Faivre-Finn, The Christie NHS Foundation Trust, Manchester, United Kingdom

16:45 - 17:00 Q&A and discussion

17:15 - 18:15 Type: Industry Satellite Symposium Room N03

Title: AstraZeneca - Key advances shaping the future of lung cancer
treatment
Moderation: Marina Garassino, United States of America

17:15 - 17:30 Recent advances in the landscape for early-stage lung cancer with no actionable genomic
alterations
Ernest Nadal, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet
de Llobregat, Spain

Last update: 05-03-2025 10:21:13am

 17:30 - 17:50 Evidence in Practice: Case Discussions in Limited-Stage SCLC and Early-Stage NSCLC
Thomas John, Peter MacCallum Cancer Centre, Melbourne, Australia

17:50 - 18:05 Future Perspectives in NSCLC

Marina Garassino, University of Chicago Department of Medicine - Section of
Hematology/Oncology, Chicago, United States of America

18:05 - 18:15 Panel discussion and Q&A

Marina Garassino, University of Chicago Department of Medicine - Section of
Hematology/Oncology, Chicago, United States of America

17:15 - 18:15 Type: Industry Satellite Symposium Room N02

Title: Pfizer Oncology - Redefining standards in 1L ALK+ aNSCLC treatment
Moderation: Ben Solomon, Australia

17:15 - 17:18 Welcome and introduction

Ben Solomon, Peter MacCallum Cancer Center, Melbourne, Australia

17:18 - 17:33 Redefining treatment standards for 1L ALK+ aNSCLC

Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne,
Switzerland

17:33 - 18:13 Optimising the patient experience in 1L ALK+ aNSCLC

Ibiayi Dagogo-Jack1, Ben Solomon2, 1Massachusetts General Hospital - Surgical Oncology

Division, Boston, United States of America, 2Peter MacCallum Cancer Center, Melbourne,
Australia

18:13 - 18:15 Summary and close

Ben Solomon, Peter MacCallum Cancer Center, Melbourne, Australia

Last update: 05-03-2025 10:21:13am

 28.03.2025
08:15 - 09:45 Type: Educational session Room N02
Title: Update on the treatment of mesothelioma
Moderation: Isabelle Schmitt-Opitz, Switzerland; Paul van Schil, Belgium

08:15 - 08:35 Current role of chemo- and immunotherapy for pleural mesothelioma
Arnaud Scherpereel, DRC / CHRU of Lille, Lille, France

08:35 - 08:55 What have we learnt from MARS 2?

Eric Lim, Royal Brompton Hospital, London, United Kingdom

08:55 - 09:15 What have we learnt from EORTC 1205?

Jo Raskin, Department of Pulmonology and Thoracic Oncology, Antwerp University Hospital
(UZA), Edegem, Belgium

09:15 - 09:35 TNM 9 and resectability of pleural mesothelioma

Isabelle Schmitt-Opitz, USZ - University Hospital Zürich, Zurich, Switzerland

09:35 - 09:45 Q&A and discussion

08:25 - 09:45 Type: Mini Oral session Room South Paris

Title: Mini Oral session 2
Moderation: Thierry Berghmans, Belgium; Sabina Berezowska, Switzerland

08:25 - 08:30 262MO - Real-World Validation of Artificial Intelligence-defined Lung Nodule Malignancy
Score (qXR-LNMS) in Predicting Risk of Lung Cancer
Deniz Koksal, Hacettepe University - Faculty of Medicine, Ankara, Türkiye

08:30 - 08:35 11MO - AI-Based Prediction of Long-Term Survival in NSCLC Patients Treated with
Immunotherapy: Insights from the Multicentric APOLLO11 Study
Vanja Miskovic, Politecnico di Milano, Milan, Italy

08:35 - 08:45 Invited Discussant 262MO and 11MO

08:45 - 08:50 297MO - Patterns of disease progression with durvalumab (D) after concurrent
chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Results from
ADRIATIC
Suresh Senan, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer
Center Amsterdam, Amsterdam, Netherlands

08:50 - 08:55 239MO - Stratification of pleural mesothelioma patients for combined immunotherapy
based on sarcomatoid component and tumour microenvironment markers in the IFCT-
MAPS2 study
Guillaume Tosato, Sorbonne Université, Paris, France

Last update: 05-03-2025 10:21:13am

 08:55 - 09:05 Invited Discussant 297MO and 239MO
Thierry Berghmans, Institute Jules Bordet, Brussels, Belgium

09:05 - 09:10 135MO - Grading system of Spread Through Air Spaces is an Independent Predictor of
Recurrence in Stage I Invasive Non-Mucinous Adenocarcinoma
Joonseok Lee, SNUBH - Seoul National University Bundang Hospital, Seongnam, Republic of
Korea

09:10 - 09:15 136MO - Predictors of multidisciplinary tumor board adherence in stage III non small-cell
lung cancer patients from a large multicenter study
Markus Joerger, Kantonsspital St. Gallen, St. Gallen, Switzerland

09:15 - 09:25 Invited Discussant 135MO and 136MO

Sabina Berezowska, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

09:25 - 09:30 137MO - Impact of cardiac substructure dose on cardiotoxicity and Overall Survival (OS) in
Early-Stage Non-Small Cell Lung Cancer (ES-NSCLC) patients receiving Stereotactic
Ablative Body Radiotherapy (SABR): data from the interim analysis of the LUNG HEART
Study
Marzia Cerrato, University of Torino, Turin, Italy

09:30 - 09:35 189MO - Perioperative Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients

With Stage IIIA(N2) Non-Small-Cell Lung Cancer - Final analysis of the trial SAKK 16/14
Sacha Rothschild, Universitätsspital Basel, Basel, Switzerland

09:35 - 09:45 Invited Discussant 137MO and 189MO

Yolande Lievens, Ghent, Belgium

08:45 - 09:45 Type: Controversy session Room N03

Title: Electronic cigarettes for smoking cessation

08:45 - 08:55 Introduction and first vote

08:55 - 09:15 PRO: Harm reduction

09:15 - 09:35 CON: Harm re-introduction

09:35 - 09:45 Second vote and conclusions/discussion

09:45 - 10:15 Type: Coffee break Foyer

Title: Coffee break

10:15 - 11:45 Type: Educational session Room N03

Title: ESTS: Challenging scenarios for the modern lung cancer surgeon
Moderation: Alessandro Brunelli, United Kingdom; Nuria Novoa, Spain

Last update: 05-03-2025 10:21:13am

 10:15 - 10:35 Is a wedge resection equivalent to segmentectomy for a peripheral stage IA1-2 solid
NSCLC?
Agathe Seguin-Givelet, IMM - Institut Mutualiste Montsouris, Paris, France

10:35 - 10:55 Knowledge gaps in segmentectomy: What we still need to learn

Rene Petersen, Rigshospitalet, Copenhagen, Denmark

10:55 - 11:15 Surgical outcomes after neoadjuvant chemo-immunotherapy in the real World: European
experience
Alessandro Brunelli, St. James's University Hospital, Leeds, United Kingdom

11:15 - 11:35 Is it really more complex to operate on a patient after neoadjuvant chemo-
immunotherapy?
Clemens Aigner, Medical University Vienna, Vienna, Austria

11:35 - 11:45 Q&A and discussion

10:15 - 11:45 Type: Educational session Room South Paris

Title: ESTRO: How IO can change classical therapeutic approaches in SCLC?
Moderation: Umberto Ricardi, Italy; Fiona McDonald, United Kingdom

10:15 - 10:35 LS SCLC: Optimal combination of chemobeam and IO

Umberto Ricardi, Azienda Ospedaliero Universitaria San Giovanni Battista di Torino, Torino, Italy

10:35 - 10:55 Technical update on modern thoracic RT

Paul-Martin Putora, Kantonsspital St. Gallen, St. Gallen, Switzerland

10:55 - 11:15 ES SCLC: Any role for RT in IO era?

Ben Slotman, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam,
Netherlands

11:15 - 11:35 What is the role of brain RT in IO era (PCI, WBRT, SRS)
Cécile Le Pechoux, Institut Gustave Roussy, Villejuif, France

11:35 - 11:45 Q&A and discussion

10:15 - 11:45 Type: Educational session Room N02

Title: ETOP-IBCSG: Questions still unanswered in advanced NSCLC
Moderation: JORDI REMON MASIP, France; Solange Peters, Switzerland

10:15 - 10:35 Should we exclude immunotherapy in case of advanced NSCLC with oncogenic addiction?
Jordi Remon Masip, Institut Gustave Roussy, Villejuif, France

Last update: 05-03-2025 10:21:13am

 10:35 - 10:55 When can or should anti-PD(L)-1s be stopped in advanced NSCLC?
Silvia Novello, University of Turin, Orbassano, Italy

10:55 - 11:15 New developments in the treatment of immunotherapy-induced toxicities

Michel Obeid, CHUV - Centre Hospitalier Universitaire Vaudois - Bâtiment Champ de l'Air,
Lausanne, Switzerland

11:15 - 11:35 How to treat advanced large-cell neuroendocrine carcinoma?

Anne-Marie Dingemans, Erasmus MC Cancer Institute - University Medical Center, Rotterdam,
Netherlands

11:35 - 11:45 Q&A and discussion

10:15 - 11:45 Type: Patient Advocacy session Room W03

Title: Addressing minorities and disparities in diagnosis and treatment
Moderation: Noemi Reguart, Spain; Merel Hennink, Netherlands

10:15 - 10:35 A breath of change: Redefining lung cancer care for minority populations
Ory Wiesel, Baruch Padeh Medical Center, Poriya, Tiberias, Israel

10:35 - 10:55 Fighting for fairness: The advocate’s role in closing the care gap
Stefania Vallone, LuCE, Bern, Switzerland

10:55 - 11:15 Collaboration for equity: Academic centres supporting community hospitals in lung cancer
treatment
Dario Trapani, Università degli Studi di Milano, Milan, Italy

11:15 - 11:35 Health without borders: Advocacy for lung cancer patients in remote areas
Anne-Marie Baird, St. James's Hospital, Dublin, Ireland

11:35 - 11:45 Q&A and discussion

12:00 - 13:00 Type: Industry Satellite Symposium Room N02

Title: Johnson & Johnson - Transforming clinical practice in EGFR-mutant
NSCLC
Moderation: Nicolas Girard, France; Natasha Leighl, Canada

12:00 - 12:05 Welcome and introductions

Nicolas Girard, Institut Curie, Paris, France

12:05 - 12:20 Guiding treatment options for common EGFR-mutant NSCLC

Raffaele Califano, The Christie NHS Foundation Trust, Manchester, United Kingdom

Last update: 05-03-2025 10:21:13am

 12:20 - 12:40 Optimising management for patients with common EGFR mutations
Vincent Sibaud, IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France

12:40 - 12:55 Discussion

12:55 - 13:00 Closing remarks

Natasha Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto,
Canada

12:00 - 13:00 Type: Industry Satellite Symposium Room N03

Title: touchIME - Navigating the clinical impact of TROP2-targeting in
NSCLC
Moderation: Marina Garassino, United States of America

12:00 - 12:05 The emergence of TROP2 in NSCLC

Marina Garassino, University of Chicago Department of Medicine - Section of
Hematology/Oncology, Chicago, United States of America

12:05 - 12:20 Clinical impact of targeting TROP2 in NSCLC

Jarushka Naidoo, Beaumont Hospital, Dublin, Ireland

12:20 - 12:35 Clinical utility of TROP2 expression in NSCLC

David Planchard, Institut Gustave Roussy, Villejuif, France

12:35 - 12:55 Managing ADC toxicities in NSCLC clinical practice

Marina Garassino1, Jarushka Naidoo2, David Planchard3, 1University of Chicago Department of

Medicine - Section of Hematology/Oncology, Chicago, United States of America, 2Beaumont
Hospital, Dublin, Ireland, 3Institut Gustave Roussy, Villejuif, France

12:55 - 13:00 Future directions for TROP2 in NSCLC

Marina Garassino, University of Chicago Department of Medicine - Section of
Hematology/Oncology, Chicago, United States of America

13:00 - 13:45 Type: Poster Display session Poster area

Title: Poster Display session

13:00 - 13:00 12P - Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for
advanced squamous non-small-cell lung cancer (sqNSCLC): 5y update from the phase 3
CameL-sq trial
Caicun Zhou, Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China

13:00 - 13:00 13P - Brain metastases and actionable genetic alterations with sacituzumab govitecan
versus docetaxel in metastatic non-small cell lung cancer: subgroups of the phase III
EVOKE-01 trial
Enriqueta Felip, Department of Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona,
Spain

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 14P - Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer
after first-line chemoimmunotherapy: a single-arm, phase 2 trial
Zhengfei Zhu, Fudan University Shanghai Cancer Center, Shanghai, China

13:00 - 13:00 15P - Updated OS and final QoL and safety results of a randomised, open-label, phase 3
study comparing Nivolumab plus ipilimumab versus carboplatin-based doublet as first-
line treatment for patients with advanced NSCLC aged _70 years or with an ECOG PS of 2
(GFPC 08-2015 ENERGY).
Hervé Lena, CHU de Rennes - Hopital Pontchaillou, Rennes, France

13:00 - 13:00 16P - Continued cemiplimab with addition of chemotherapy beyond progression in
patients with advanced NSCLC on 1L cemiplimab monotherapy: 5-year outcomes of
EMPOWER-Lung 1
Marina Garassino, University of Chicago Department of Medicine - Section of
Hematology/Oncology, Chicago, United States of America

13:00 - 13:00 17P - Final analysis of PERLA, a global, randomized, phase 2 double-blind trial of
dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic
non-squamous non-small cell lung cancer
Sun Min Lim, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine,
Seoul, Republic of Korea

13:00 - 13:00 18P - Telisotuzumab vedotin monotherapy in patients with previously treated c-Met
protein-overexpressing non-squamous EGFR wildtype advanced NSCLC: Updated analysis
of the LUMINOSITY trial.
Nicolas Girard, Institut Curie, Paris, France

13:00 - 13:00 19P - Subgroup Analysis of First-Line Camrelizumab Plus Chemotherapy in Brain
Metastases of NSCLC: Results from the CTONG 2003 Trial
Yang-Si Li, Guangdong Provincial People's Hospital, Guangzhou, China

13:00 - 13:00 20P - Cancer Registry-Based Real-World Evidence Confirms Efficacy of Treatments
Comparable to KEYNOTE-189/-407 and Impower-133
Irina Surovtsova, Clinical State Registry Baden-Württemberg GmbH, Stuttgart, Germany

13:00 - 13:00 21P - Primary analysis of safety, efficacy and immunogenicity of the therapeutic cancer
vaccine PDC*lung01 with or without pembrolizumab in NSCLC: A multicenter phase I/II
study
Johan Vansteenkiste, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven,
Belgium

13:00 - 13:00 22P - Effects of Datopotamab deruxtecan (Dato-DXd) vs. docetaxel on patient-reported
outcomes (PROs) in adults with previously treated advanced or metastatic non squamous
(NSQ) non-small cell lung cancer (NSCLC): results from TROPION-LUNG01
Robin Cornelissen, Erasmus MC - University Medical Center, Rotterdam, Netherlands

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 23P - Early pembrolizumab clearance as a sensitive prognostic biomarker for survival in
patients with advanced non-small cell lung cancer
Rob Ter Heine, Radboud University Medical Center, Nijmegen, Netherlands

13:00 - 13:00 24P - 5-Year Real-World Outcomes With First-Line (1L) Pembrolizumab Plus (+)
Chemotherapy in Advanced/Metastatic NSCLC
Vamsidhar Velcheti, NYU Langone Medical Center and School of Medicine, New York, United
States of America

13:00 - 13:00 25P - Durvalumab with or without tremelimumab plus chemotherapy as first-line
treatment for metastatic NSCLC: Results from the phase 3 POSEIDON extended China
cohort
Jie Hu, Zhongshan Hospital Affiliated to Fudan University & Shanghai Geriatric Medical Center,
Shanghai, China

13:00 - 13:00 26P - Assessing first-line immunotherapy duration in advanced NSCLC

Simone Rota, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

13:00 - 13:00 27P - Impact of platinum-based chemotherapy (CT) on acquired resistance (AR) to first-line
immunecheckpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC): individual
patient data metanalysis
Sara Oresti, IRCCS Ospedale San Raffaele, Milan, Italy

13:00 - 13:00 28P - Sex-Based Differences in the Efficacy of PD-(L)1 Inhibitors monotherapy for advanced
Non-Small Cell Lung Cancer: A Meta-Analysis of 13 phase III studies
Thierry Landre, Hopital René Muret - AP HP, Sevran, France

13:00 - 13:00 29P - Evaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug

conjugate, in nonsquamous NSCLC participants with negative or moderate CEACAM5
expression and high circulating CEA: results from phase 2 CARMEN-LC06 trial
Hervé Lena, CHU de Rennes - Hopital Pontchaillou, Rennes, France

13:00 - 13:00 30P - Clinical Characteristics and Survival Outcomes of Long-Term Responders for
advanced Non-Small Cell Lung Cancer Patients with First-line PD-1/PD-L1 Inhibitors: A
Multicenter Retrospective Study
Zhijuan Du, Chinese PLA General Hospital (301 Military Hospital), Beijing, China

13:00 - 13:00 31P - Camrelizumab Plus Chemotherapy as First-Line Treatment for Advanced Non-
squamous NSCLC with Brain Metastases: Final overall survival results from the CAP-BRAIN
trial
Xue Hou, Sun Yat-sen University Cancer Center, Guangzhou, China

13:00 - 13:00 32P - The impact of renal dysfunction and pemetrexed administration dose in
KEYNOTE189 on prognosis.
Yuta Yamanaka, Kansai Medical University, Hirakata, Japan

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 33P - A Multi-country Time & Motion (T&M) Study of Subcutaneous (SC) vs Intravenous (IV)
Pembrolizumab (Pembro) plus Chemotherapy (Chemo) in Metastatic Non-small Cell Lung
Cancer (mNSCLC)
Erwin De Cook, Syneos Health, Madrid, Spain

13:00 - 13:00 34P - Polymeric micelles paclitaxel (pm-Pac), carboplatin combined with sintilimab in the
first-line treatment of advanced non-squamous non-small cell lung cancer(nsq-NSCLC):
Phase II study
Yun Zhou, China Pharmaceutical University - Jiangning Campus, Nanjing, China

13:00 - 13:00 35P - Clinical and safety outcomes of cancer vaccines in patients with advanced non-small
cell lung cancer after first-line therapy: a systematic review and meta-analysis
Shaoyi Chen, Peking University People's Hospital, Beijing, China

13:00 - 13:00 36P - Efficacy and safety of datopotamab deruxtecan on advanced/metastatic non-small
cell lung cancer patients: a systematic review and single-arm meta-analysis
Henrique Kim, A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, Brazil

13:00 - 13:00 37P - Tislelizumab (TIS) combined with chemotherapy (CT) as first-line (1L) therapy for
locally advanced or metastatic non-squamous non-small cell lung cancer (LA/M nsq-
NSCLC): programmed death-ligand 1 (PD-L1) expression _50% subgroup analysis of the
randomized, phase 3 RATIONALE-304 trial
Yan Yu, Harbin Medical University Cancer Hospital, Harbin, China

13:00 - 13:00 38P - Two years of follow-up data of a Phase 2 clinical trial of Atezolizumab with
Bevacizumab for patients with PD-L1 high expression non-squamous non-small cell lung
cancer (WJOG10718L/@ Be Study)
Takashi Seto, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

13:00 - 13:00 39P - Real World Efficacy and Safety of Anlotinib in NSCLC Previously Treated with
Immune Checkpoint Inhibitors
Yuchao Dong, The First Affiliated Hospital of Naval Medical University/Changhai Hospital of
Shanghai, Shanghai, China

13:00 - 13:00 40P - Metformin Plus/Minus Cyclic Fasting Mimicking Diet to improve the Efficacy of First
Line Chemo-immunotherapy in Advanced LKB1-inactive NSCLC: results of the phase II
trial FAME
Mario Occhipinti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

13:00 - 13:00 41P - NETWORK META-ANALYSIS (NMA) OF THE FIRST-LINE THERAPY FOR ADVANCED NON-
SQUAMOS NON-SMALL CELL LUNG CANCER (nsNSCLC): DOES PD-L1 EXPRESSION MODIFY
EFFECT OF THE IMMUNOTHERAPY ON THE OVERALL SURVIVAL (OS)?
Mikhail Fedyanin, National Medical Research Center of Oncology named after N.N. Blokhin,
Moscow, Russian Federation

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 42P - First-line (1L) nivolumab (N) + ipilimumab (I) with 2 cycles of platinum-based
chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC):
Interim data from the German non-interventional study (NIS) FINN
Christian Schumann, Klinikverbund Allgäu gGmbH - Klinikum Kempten, Kempten, Germany

13:00 - 13:00 43P - Phase Ia study of MIDRIX4-LUNG, a tetravalent autologous dendritic cell
immunotherapy, in patients with metastatic non-small cell lung cancer
Dieter Stevens, UZ Gent - Universitair Ziekenhuis Gent, Gent, Belgium

13:00 - 13:00 44P - First line chemo-immunotherapy prognostic factors predicting Non Small cell Lung
Cancer (NSCLC) overall survival: multicentric observational study.
Riccardo Ronga, Azienda Ospedaliera Universitaria Federico II, Napoli, Italy

13:00 - 13:00 45P - Extended Follow-Up Confirmed Real-World Efficacy and Safety of Cemiplimab
Monotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1
Expression
Silvia Masini, Humanitas University, Milan, Italy

13:00 - 13:00 46P - Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-
line treatment in patients with non-small cell lung cancer: a retrospective study
Shaorong Yu, Jiangsu Cancer Hospital, Nanjing, China

13:00 - 13:00 47P - Efficacy and safety of cadonilimab-based therapies in non-small cell lung cancer
patients with progression after immunotherapy
Shaorong Yu, Jiangsu Cancer Hospital, Nanjing, China

13:00 - 13:00 48P - Real world evaluation of ipilimumab (Ipi)/Nivolumab (Nivo) in combination with two
cycles of chemotherapy in patients (pts) with Programmed Death-Ligand (PD-L1) negative
advanced non-small cell lung cancer (aNSCLC): interim results of the RW-9LA study.
Lore Decoster, UZ Brussel - Universitair Ziekenhuis Brussel, Jette, Belgium

13:00 - 13:00 49P - Phase 2 study of telomere-targeting agent THIO sequenced by cemiplimab in
Immune checkpoint Inhibitor-resistant advanced NSCLC: Interleukin-6 as a potential
predictive biomarker.
Tomasz Jankowski, Medical University of Lublin, Lublin, Poland

13:00 - 13:00 50P - The impact of prior bevacizumab on the efficacy of anlotinib in advanced non-
squamous non-small cell lung cancer
Jiale Wang, Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai,
China

13:00 - 13:00 51P - Impact of Body Mass Index on Immunotherapy Outcomes and Survival in Advanced
NSCLC
Walid Shalata, Soroka University Medical Center, Beer Sheva, Israel

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 52P - Does Timing of Immunotherapy Infusion Influence Clinical Outcomes in Non-Small
Cell Lung Cancer?
Ivánia Furtado, Centro Hospitalar de Lisboa Central (CHLC)-Hospital de Santo António dos
Capuchos (HSAC), Lisbon, Portugal

13:00 - 13:00 53P - Characterisation of benefit-risk by pemetrexed (pem) exposure in patients (pts) with
EGFRm aNSCLC treated with 1L osimertinib (osi) + platinum-pem in FLAURA2
David Planchard, Institut Gustave Roussy, Villejuif, France

13:00 - 13:00 54P - Efficacy and Safety of Firmonertinib 160mg Combined with Intrathecal Injection
Pemetrexed in NSCLC Patients with EGFR Mutations and Leptomeningeal Metastases
Xiaoyan Li, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

13:00 - 13:00 55P - Clinical value and optimal timing of cranial stereotactic radiotherapy for third-
generation EGFR-TKI-treated NSCLC with baseline limited brain metastases
Silai Yu, Fudan University Affiliated Cancer Hospital, Shanghai, China

13:00 - 13:00 56P - Initial Analysis of a Multicenter Prospective and Retrospective Cohort Study in EGFR-
Mutated Non-small Cell Lung Cancer Patients in Korea
Chan Kwon Park, The Catholic University of Korea Yeouido St. Mary's Hospital, Seoul, Republic of
Korea

13:00 - 13:00 57P - Safety and Efficacy of Aumolertinib Treatment in Patients with advanced NSCLC
Harboring 20ins and uncommon EGFR Mutations (AIM)
Wen Feng Fang, Sun Yat-Sen University Cancer Center, Guangzhou, China

13:00 - 13:00 58P - Subcutaneous (SC) after intravenous (IV) amivantamab in advanced NSCLC: Initial
results from PALOMA-2
Sun Min Lim, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine,
Seoul, Republic of Korea

13:00 - 13:00 59P - Evaluating the Effectiveness of Amivantamab Plus Lazertinib in CHRYSALIS-2 vs
EGFR TKI Monotherapy in a Matched Real-world Cohort of Participants with Atypical EGFR-
mutated Advanced NSCLC
Pascale Tomasini, Assistance Publique Hopitaux de Marseille, Marseille, France

13:00 - 13:00 60P - The FIN-EGFR study: A retrospective observational study to investigate the treatment
landscape and outcomes of early and advanced stage patients with EGFR mutated non-
small cell lung cancer (NSCLC)
Aija Knuuttila, Helsinki University Hospital, Helsinki, Finland

13:00 - 13:00 61P - Response to first-line osimertinib plus pemetrexed/carboplatin in EGFR-mutant

advanced NSLCLC with high PD-L1 expression
Chengdi Weng, Guangdong Province People's Hospital, Guangzhou, China

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 62P - Firmonertinib (formerly furmonertinib) combined with anlotinib in patients with
treatment-naive EGFR-mutant non-small-cell lung cancer: updated results from FOCUS-A
study
Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

13:00 - 13:00 63P - Osimertinib for patients with EGFRm non-small cell lung cancer: analysis of the
locally advanced/metastatic cohort (OSIREAL study)
Delvys Rodriguez Abreu, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran
Canaria, Spain

13:00 - 13:00 64P - A real-world study of furmonertinib in uncommon EGFR mutated non-small cell lung
cancer with central nervous system metastasis
Shen Cun Fang, Nanjing Chest Hospital - Medical School of Southeast University, Nanjing, China

13:00 - 13:00 65P - Real-World Treatment Patterns Among Patients with Advanced NSCLC Treated with
Amivantamab
David Waterhouse, OHC, Cincinnati, United States of America

13:00 - 13:00 66P - Long-term Follow-up of Limertinib (ASK120067) in Patients with Locally Advanced or
Metastatic EGFR T790M NSCLC: A multicentre, single-arm, phase 2b study
Lin Wu, Hunan Cancer Hospital, Changsha, China

13:00 - 13:00 67P - A Phase II Study of Sunvozertinib Combined with Anlotinib in EGFR-TKIs resistant
EGFRm Advanced NSCLC Patients?WU-KONG9?
Jie Hu, Zhongshan Hospital Affiliated to Fudan University & Shanghai Geriatric Medical Center,
Shanghai, China

13:00 - 13:00 68P - Survival Impact of Immunotherapy(IO) after Chemo-failure in EGFR-mutated NSCLC?
A post-hoc analysis of the Orient-31 trial
Ziming Li, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

13:00 - 13:00 69P - PET/Fluorescence Dual-Modal Tracing for Targeted Inhibition of RRM2 to Overcome
Osimertinib Resistance in Lung Cancer
Jinyu Zhu, Peking University, Beijing, China

13:00 - 13:00 70P - Amivantamab monotherapy in patients with pre-treated NSCLC with EGFR Exon 20
Insertion Mutations: Real-World Data on efficacy and safety from the Italian biomarker
ATLAS database
Antonio Passaro, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy

13:00 - 13:00 71P - FIN-EGFRprint: A retrospective observational study to investigate treatments and
outcomes in patients with epidermal growth factor receptor-mutated (EGFRm) advanced
Non-Small Cell Lung Cancer (aNSCLC) in Finland
Aija Knuuttila, Helsinki University Hospital, Helsinki, Finland

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 72P - Optimizing Treatment Strategies for EGFR 21L858R mutation Non-Small Cell Lung
Cancer with Brain Metastases: A Real-world Analysis of First-Line EGFR-TKI Efficacy
Likun Chen, Sun Yat-Sen University Cancer Center, Guangzhou, China

13:00 - 13:00 73P - Real-World Post-progression Analysis of First-Line Osimertinib for EGFR-mutated
advanced NSCLC in China (FLOURISH Study)
Jianya Zhou, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou,
China

13:00 - 13:00 74P - First line treatment in epidermal growth factor receptor (EGFR)-mutated non-small
cell lung cancer (NSCLC): a review and individual patient data (IPD) comparison of phase 3
clinical trials
Andrea Torchia, Sapienza - Università di Roma, Rome, Italy

13:00 - 13:00 75P - Firmonertinib plus anlotinib for first-line treatment of advanced EGFR L858R
mutated non-small cell lung cancer
Zhou Jin, Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine,
UESTC, Chengdu, China

13:00 - 13:00 76P - Long-term survival outcomes with first-line (1L) osimertinib monotherapy and
subsequent treatment (tx) patterns: Final analysis of a real-world (rw) study in US patients
(pts) with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell
lung cancer (NSCLC)
Frank Griesinger, Pius Hospital Oldenburg, Oldenburg, Germany

13:00 - 13:00 77P - EGFR-mutant Advanced NSCLC Patients Continuously Benefit From Aumolertinib as
Post Secone-Line Treatment
Zhihua Liu, Jiangxi Cancer Hospital, Nanchang, China

13:00 - 13:00 78P - Balancing Efficacy and Safety: Systematic Review of Osimertinib Plus Chemotherapy
in advanced EGFR-Mutated NSCLC
Omar Daas, IAU - The University of Jordan, Amman, Jordan

13:00 - 13:00 79P - Efficacy outcomes of larotrectinib by prior therapy and performance status in
patients with TRK fusion lung cancer
Victor Moreno Garcia, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

13:00 - 13:00 80P - Final Overall Survival and Long-term Safety Outcomes of Savolitinib in Patients with
Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 (METex14) Mutation: An
Update from a Phase 3b Study
Yongfeng Yu, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

13:00 - 13:00 81P - Tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung
cancer (NSCLC) from the VISION study: _3-year follow-up outcomes
Julien Mazieres, Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, France

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 82P - A retrospective real-world evidence study of MTAP status and clinical outcomes in
patients with advanced non-small cell lung cancer
Adrian Sacher, University of Toronto, Toronto, Canada

13:00 - 13:00 83P - Efficacy and safety of lorlatinib in patients with ALK+ metastatic non-small cell lung
cancer (mNSCLC) previously treated with an ALK inhibitor: results from a phase 4 study
Alessandra Bearz, CRO National Cancer Institute, Aviano, Italy

13:00 - 13:00 84P - High Prevalence of Actionable Driver Alterations in Lung Cancer Patients with
Germline MUTYH Mutations
Zhaohui Arter, UCI Health - University of California Irvine, Orange, United States of America

13:00 - 13:00 85P - Phase I results from the Phase I/II POTENT trial of Tepotinib and Pembrolizumab in
Non-Small Cell Lung Cancer (NSCLC)
Kira-Lee Koster, Kantonsspital St. Gallen, St. Gallen, Switzerland

13:00 - 13:00 86P - Diagnosis and treatment patterns in adults with metastatic non-small cell lung
cancer with BRAF V600E mutation in clinical practice: An international ambispective real-
world study (OCTOPUS)
David Planchard, Institut Gustave Roussy, Villejuif, France

13:00 - 13:00 87P - Genomic Alterations and Resistance Mechanisms in ALK-Rearranged Non-Small Cell
Lung Cancer: Insights from NGS Profiling and Clinical Outcomes
Paolo Ambrosini, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

13:00 - 13:00 88P - Real-World Occurrence of Early-Onset Pulmonary Events With Brigatinib for
Advanced ALK+ NSCLC
Maximilian Hochmair, Klinik Floridsdorf - Wiener Gesundheitsverbund, Vienna, Austria

13:00 - 13:00 89P - Clinical Characteristics, Treatment Patterns, and Outcomes of First-line Brigatinib in
Patients with Advanced ALK+ NSCLC: A Multinational Real-World Study
Sharmistha Ghosh, Guy's and St. Thomas' Hospital NHS Foundation Trust, London, United
Kingdom

13:00 - 13:00 90P - Efficacy of subsequent therapy following the progression of crizotinib in advanced
ROS1+ NSCLC in real word setting
Zihua Zou, Chinese Academy of Medical Sciences and Peking Union Medical College - National
Cancer Center, Beijing, China

13:00 - 13:00 91P - Intracranial efficacy of crizotinib in advanced ROS1+NSCLC in real world setting
Zihua Zou, Chinese Academy of Medical Sciences and Peking Union Medical College - National
Cancer Center, Beijing, China

13:00 - 13:00 92P - Real-World Treatment Sequencing and Outcomes in ALK-Positive Metastatic Non-
Small Cell Lung Cancer
Martin Dietrich, The US Oncology Network, The Woodlands, United States of America

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 93P - Next generation ALK inhibitors and metastatic NSCLC with ALK gene
rearrangements, a 2x2 head to head comparison using RWD from TriNetX database.
Carlos Henrique Andrade Teixeira, Centro de Oncologia do Hospital Alemão Oswaldo Cruz &
CATSMI, Sao Paulo, Brazil

13:00 - 13:00 94P - Long-term Efficacy of Lorlatinib vs Alectinib in Patients With and Without
Brain/Central Nervous System Metastases: Matching-Adjusted Indirect Comparisons
Julien Mazieres, Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, France

13:00 - 13:00 95P - Adagrasib (ADA) plus cetuximab (CETUX) in patients (pts) with advanced KRASG12C-
mutated non-small cell lung cancer (NSCLC) from KRYSTAL-1
Jun Zhang, KUMC - University of Kansas Medical Center, Kansas City, United States of America

13:00 - 13:00 96P - Enhanced anti-tumor activity of zelenectide pevedotin in patients (pts) with non-
small cell lung cancer (NSCLC) with NECTIN4 gene amplification (amp)
Loic Verlingue, Centre Léon Bérard, Lyon, France

13:00 - 13:00 97P - Matching-adjusted indirect comparison (MAIC) of sotorasib vs adagrasib for
previously treated advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation
Jurgen Wolf, Universitätsklinikum Köln (AöR), Cologne, Germany

13:00 - 13:00 98P - Exploratory Analysis Showed Increased Overall Survival among Non-Small Cell Lung
Cancer (NSCLC) Patients with Mutated KRAS Compared with Wildtype KRAS in a Phase 2
Trial of Mecbotamab Vedotin (CAB-AXL-ADC)
Karen Reckamp, Cedars-Sinai Medical Center, Los Angeles, United States of America

13:00 - 13:00 99P - The effect of KRAS mutation subtypes on the efficacy of first-line pembrolizumab in
stage IV non-small cell lung cancer patients with high PD-L1 expression.
Patrizia Froesch, Oncology Institute of Southern Switzerland IOSI, Locarno, Switzerland

13:00 - 13:00 100P - Clinical spectrum and outcomes of KRAS mutated advanced stage NSCLC.
An-Sofie D'Hulster, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven,
Belgium

13:00 - 13:00 101P - European Results from the 2024 International Association for the Study of Lung
Cancer (IASLC) Global Survey on Biomarker Testing
Matthew Smeltzer, University of Memphis, MEMPHIS, United States of America

13:00 - 13:00 102P - Molecular characteristics and spatially resolved proteomic immune clusters reveal
responsiveness of large cell neuroendocrine carcinomas of the lung (LCNEC) towards the
Checkmate-9LA treatment protocol
Matthias Mueller, Bundeswehrkrankenhaus Ulm, Ulm, Germany

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 103P - Enhancing Survival Prediction in Advanced Non-Small Cell Lung Cancer (aNSCLC): A
comparison of Artificial Intelligence (AI) derived prognostication and RECIST Assessments
in MYSTIC Phase 3 Trial
Omar Khan, Tom Baker Cancer Centre, Calgary, Canada

13:00 - 13:00 104P - MOMENT disease registry: Patient characteristics and treatment patterns from
interim enrollment analysis of patients (pts) with advanced non-small cell lung cancer
(NSCLC) harboring MET exon 14 (METex14) skipping treated with systemic therapy
Michael Thomas, Universitätsklinikum Heidelberg, Heidelberg, Germany

13:00 - 13:00 105P - Evaluating Survival and Treatment Outcomes in Non-Small Cell Lung Cancer
(NSCLC): A SEER Database Analysis of Demographic, Socioeconomic, and Clinical Factors
Mai Abdelkader, Suez Canal University Hospital, Ismailia, Egypt

13:00 - 13:00 106P - AI-Driven Disease and Care Modelling and Simulation: A Framework for Simulating
Real-World Scenarios in Non-Small Cell Lung Cancer (NSCLC)
Antoine Movschin, Quinten Health, Paris, France

13:00 - 13:00 107P - Quality of life in a real-world prospective lung cancer cohort during palliative
immunotherapy
Ida Meklenborg, OUH - Odense University Hospital, Odense, Denmark

13:00 - 13:00 108P - The Information-seeking Behaviour of Health Care Providers for Drug-Drug
Interaction Signals with Lung Cancer Agents
David Burger, Radboud University Medical Center, Nijmegen, Nijmegen, Netherlands

13:00 - 13:00 109P - Enhancing Enrollment to 1L NSCLC Trials By Allowing 1 Prior Cycle of Standard of
Care (SOC): SUNRAY-01 Experience
Maximilian Hochmair, Klinik Floridsdorf - Wiener Gesundheitsverbund, Vienna, Austria

13:00 - 13:00 110P - Prediction of the Individual Risk for the Development of Brain Metastases in
Patients with Stage IV NSCLC without Actionable Genomic Alterations - Data from the
German CRISP Registry (AIO-TRK-0315)
Fabian Acker, Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt
am Main, Germany

13:00 - 13:00 111P - A web-based calculator to Predict the Occurrence of Severe Immune-Related
Adverse Events in Non-Small Cell Lung Cancer: Based on a Prospective Study
Peng Song, PUMCH-Peking Union Medical College Hospital (East), Beijing, China

13:00 - 13:00 112P - The Role of Socioeconomic Status (SES) in Non-Small Cell Lung Carcinoma (non-
adenocarcinoma) Outcomes: A Two-Decade Perspective from Brazil
Fernanda Malucelli Favorito, Faculdade de Ciencias Medicas da Santa Casa de Sao Paulo, Sao
Paulo, Brazil

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 113P - Real-world treatment options for metastatic NSCLC patients following progression
on chemo-immunotherapy
Alessio Cortellini, Policlinico Universitario Campus Bio-Medico, Rome, Italy

13:00 - 13:00 114P - Feasibility of Electronic Patient-Reported Outcomes (ePRO) Assessment Using a
Mobile App to Monitor Patients with Advanced ALK+ NSCLC (ePROtector Study)
Diego Enrico, Instituto Alexander Fleming, Buenos Aires, Argentina

13:00 - 13:00 115P - Exploring Hypofractionated Thoracic Radiotherapy in Stage IV NSCLC: Insights from
a Real-World Retrospective Study
Sina Mansoorian, LMU - Ludwig Maximilians University of Munich, Munich, Germany

13:00 - 13:00 116P - Predicting Overall Survival (OS) Differences and Treatment Duration from
Longitudinal AI-Driven Imaging-Based Prognostication (IPRO) and First-Line (1L)
Treatment Status Among Patients with Advanced Non-Small Cell Lung Cancer (aNSCLC)
Omar Khan, Tom Baker Cancer Centre, Calgary, Canada

13:00 - 13:00 117P - Natural Language Processing (NLP)-Driven Analysis of Metastatic Non-Small Cell
Lung Cancer (mNSCLC) Outcomes: A Real-World (RW) Study within Israel's Universal
Healthcare
Renana Barak, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, Israel

13:00 - 13:00 118P - Assessing informative censoring in trials testing immune-checkpoint inhibitors in
NSCLC: A systematic review and a meta-research study
Filippo Vitale, Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli,
Italy

13:00 - 13:00 119P - Real-world first-line (1L) treatment characteristics and physician-reported areas of
improvement for patients with advanced non-small cell lung cancer (aNSCLC) with PD-L1
expression _50% and without actionable genomic alternations (AGA) in Europe (EU), United
States (US) and Asia
Martin Sebastian, Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität),
Frankfurt am Main, Germany

13:00 - 13:00 120P - poorly differentiated lung adenocarcinoma: Recent trends, Clinicopathological
features and survival outcomes
Dina Hassan, Suez Canal University Hospital, Ismailia, Egypt

13:00 - 13:00 121P - Clinical Application and Potential Benefits of En-bloc Biopsy Based on Minimally
Invasive Surgery for Advanced Lung Cancer
Jianfu Li, State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of
Guangzhou, Guangzhou, China

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 122TiP - TROPION-Lung10: Phase 3 study of datopotamab deruxtecan (Dato-DXd) +
rilvegostomig in non-squamous (NSQ) advanced/metastatic (a/m) non-small cell lung
cancer (NSCLC) with high PD-L1 expression and without actionable genomic alterations
(AGAs)
Thomas Newsom-Davis, Chelsea and Westminster Hospital - NHS Trust, London, United Kingdom

13:00 - 13:00 123TiP - TROPION-Lung14: A phase 3 study of osimertinib _ datopotamab deruxtecan

(Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or
metastatic (LA/M) non-small cell lung cancer (NSCLC)
Sarah Goldberg, Yale University School of Medicine - Yale Cancer Center, New Haven, United
States of America

13:00 - 13:00 124TiP - TROPION-Lung15: A phase 3 study of datopotamab deruxtecan (Dato-DXd) _

osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally
advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on
prior osimertinib
Ernest Nadal, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet
de Llobregat, Spain

13:00 - 13:00 125TiP - Phase 1 study of patritumab deruxtecan (HER3-DXd) in patients (pts) with
advanced KRAS G12C non-small cell lung cancer (NSCLC): Study U102 cohort 5
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, Spain

13:00 - 13:00 126TiP - An Open-Label, Single-Arm, Phase Ib Exploratory Study to Evaluate the Safety and
Efficacy of Golidocitinib in Combination with Anti-PD-1 in Locally Advanced or Metastatic
Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1 Containing Regimens
Hua Zhong, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

13:00 - 13:00 127TiP - RELATIVITY-1093: a randomized, phase 3 study of first-line nivolumab (NIVO) +
relatlimab (RELA) high dose (HD) with platinum-doublet chemotherapy (PDCT) vs
pembrolizumab (PEMBRO) + PDCT in patients with metastatic NSCLC having tumor PD-L1
expression _ 1% and non-squamous (NSQ) histology
Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne,
Switzerland

13:00 - 13:00 128TiP - ABBIL1TY NSCLC-06: A Global, Randomized, Open-Label, Phase 3 Trial of
Acasunlimab in Combination With Pembrolizumab (Pembro) vs Docetaxel in Checkpoint
Inhibitor (CPI)-Experienced Patients With PD-L1+ Metastatic Non-Small Cell Lung Cancer
(mNSCLC)
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, Spain

13:00 - 13:00 129TiP - A single arm phase II study evaluating intracranial efficacy of Sacituzumab
Govitecan (SG) with bevacizumab (BEV) in patients (pts) with active, asymptomatic brain
metastases (BM) from non-small cell lung cancer (NSCLC)
Lizza Hendriks, Maastricht University Medical Center (MUMC), Maastricht, Netherlands

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 130TiP - High-Dose Aumolertinib as First-Line Treatment in Advanced NSCLC Patients
harboring EGFR 21L858R Mutation (AHEAD)
Li Ping Lin, The Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou,
China

13:00 - 13:00 131TiP - TACTI-004: a double-blinded, randomized phase 3 trial in patients with
advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II
agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P
+C
Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

13:00 - 13:00 132TiP - Phase 1b open-label study of trastuzumab deruxtecan (T-DXd) + rilvegostomig _
carboplatin as first-line (1L) treatment (Tx) for metastatic HER2-overexpressing (HER2-OE)
non-small cell lung cancer (NSCLC): DESTINY-Lung03 (DL-03) Part 4
David Planchard, Institut Gustave Roussy, Villejuif, France

13:00 - 13:00 133TiP - A Randomized Phase 3 Study of Ivonescimab Versus Pembrolizumab as First-Line
Treatment of Metastatic Non-Small Cell Lung Cancer as First-Line Treatment of Metastatic
Non-Small Cell Lung Cancer With High Tumor PD-L1 Expression: HARMONi-7
Antonio Passaro, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy

13:00 - 13:00 134TiP - Evaluation of an additional cohort of patients with non-small cell lung cancer
(NSCLC) in the Phase 1/2 Duravelo-1 study of zelenectide pevedotin (BT8009), a Bicycle
Toxin Conjugate
Capucine Baldini, Institut Gustave Roussy, Villejuif, France

13:00 - 13:00 138P - Outcomes by treatment (tx) cycles (cyc) with perioperative nivolumab (NIVO) in
patients (pts) with resectable NSCLC from CheckMate 77T study
Denis Moro-Sibilot, CHU Grenoble-Alpes - Le site nord à La Tronche - Hopital Michallon, La
Tronche, France

13:00 - 13:00 139P - Global qualitative assessment of factors affecting multidisciplinary team (MDT)
care in early-stage NSCLC
Severin Schmid, University Medical Center Freiburg, Freiburg im Breisgau, Germany

13:00 - 13:00 140P - Neoadjuvant lazertinib therapy guided by EGFR mutation detection in BALF for
resectable lung cancer: Prospective real-world phase 2 study.
In Ae Kim, Konkuk University Medical Center, Seoul, Republic of Korea

13:00 - 13:00 142P - Identification of the Lymph Node Metastasis Atlas and Optimal Lymph Node
Dissection Strategy in Patients with Resectable Lung Invasive Mucinous Adenocarcinoma:
A Real-World Multicentre Study
Jie He, Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing,
China

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 143P - Microwave Ablation Versus Lobectomy for Ground-Glass Opacity Nodules in the
Hilar Region: A Multicenter Prospective Real-World Study on Efficacy and Safety
Wangrui Liu, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
Shanghai, China

13:00 - 13:00 144P - Perioperative Immunotherapy Treatment in Resectable Non-Small Cell Lung Cancer
with KRAS Mutation: A Real-World Study (Peri-R-01)
Hua Zhong, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

13:00 - 13:00 145P - Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I A
NSCLC with High risk factors and EGFR-sensitizing Mutations (APPOINT)
Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

13:00 - 13:00 146P - Sex Differences in Patient-reported Outcomes Following Pulmonary Resection for
Lung Cancer: A Systematic Review
Rita Costa, CHUSJ, porto, Portugal

13:00 - 13:00 147P - Radiomics-based multivariate classifiers to decode Tumor Immune

Microenvironment heterogeneity in surgically resected NSCLC patients
Prisca Tamarozzi, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

13:00 - 13:00 148P - Histological Grade 3 in Stage 1A Lung Cancer: Survival Risks Comparable to Stage 1B
Gyerim Park, The Catholic University of Korea - Seoul St.Mary Hospital, Seoul, Republic of Korea

13:00 - 13:00 149P - Comparative investigation of neoadjuvant chemoimmunotherapy versus

perioperative (chemo)immunotherapy in resectable non-small cell lung cancer: A real-
world retrospective study
Sini Li, Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer
Hospital, Hangzhou, China

13:00 - 13:00 150P - Pathologic complete response (pCR) and major pathologic response (MPR) as
surrogate endpoints of survival in immunotherapy trials for early-stage NSCLC
Marco Tagliamento, Università degli Studi di Genova e Ospedale Policlinico San Martino IRCCS -
DiMI, Genova, Italy

13:00 - 13:00 151P - Real-world Adjuvant Treatment Patterns in Chinese Patients with Resected Stages I
to III EGFR-mutated NSCLC: A Multi-center Observational Study (ADDRESS, CATO-2001)
Wenhua Liang, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

13:00 - 13:00 153P - Empowering Early Detection: A Community-Based Approach to Lung Cancer
Screening in Nigeria's Underserved Populations
Vitus Ejiogu, Ahmadu Bello University, Zaria, Nigeria

13:00 - 13:00 154P - Prognostic Significance of T Cell Subtypes in the Tumour Microenvironment for
Recurrence Following Curative-Intent Resection in Early-Stage NSCLC
Anna Mcguire, UBC - University of British Columbia - Faculty of Medicine, Vancouver, Canada

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 155P - Survival after wedge resection, segmentectomy and lobectomy for clinical stage IA
non-small cell lung cancer: a network meta-analysis and systematic review
Shen Jianfei, Taizhou Hospital of Zhejiang Province, Taizhou, China

13:00 - 13:00 156P - Sublobar Resections for Stage I NSCLC: A Real-World Validation of Clinical Trials
Through an Individual Patient Data Meta-Analysis
Filippo Tommaso Gallina, IRCCS Regina Elena National Cancer Institute (IRE), Rome, Italy

13:00 - 13:00 157P - Comparative Long-Term Oncological Outcomes of Single-Port and Multi-Port VATS
in Early-Stage NSCLC: Is Single-Port VATS Oncologically Effective?
Dohyung Kim, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea

13:00 - 13:00 158P - Impact of Preserved Ratio Impaired Spirometry on Postoperative Outcomes of Non-
Small Cell Lung Cancer Surgery
Boksoon Chang, Samsung Medical Center (SMC), Seoul, Republic of Korea

13:00 - 13:00 159P - Patient and clinician preferences for adjuvant treatment in early-stage non-small
cell lung cancer (NSCLC)
Anastasia Doldos, Evidera Ltd, London, United Kingdom

13:00 - 13:00 160P - Comparison of Outcomes Between Anatomical Segmentectomy and Stereotactic
Body Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer: A Single-Center
Retrospective Analysis
Rita Costa, CHUSJ, porto, Portugal

13:00 - 13:00 161P - Comparative Analysis of two cohorts of Patients with NSCLC: Persistent disease vs
complete response after neoadjuvant treatment with chemoimmunotherapy
Maria Sereno, Hospital Universitario Infanta Sofía, San Sebastian de los Reyes, Spain

13:00 - 13:00 162P - A Real world study of Adjuvant furmonertinib in patients with stage IA-IIIA EGFR-
mutant non-small-cell lung cancer
Jiayue Ye, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China

13:00 - 13:00 163P - Transportability of RATIONALE-315 trial outcomes to the European patient
population in resectable non-small cell lung cancer
Francesco Passiglia, Università Degli Studi Di Torino - Orbassano, Orbassano, Italy

13:00 - 13:00 164P - The Clinical Response and Safety of Neoadjuvant Alectinib in Lung Adenocarcinoma
with ALK Rearrangement: A Two-Center Retrospective Study
Liang Shi, Beijing Chest Hospital, Capital Medical University, Beijing, China

13:00 - 13:00 165P - Adjuvant Aumolertinib for Resected EGFR-Mutated Stage IA2-?A Non-Small-Cell
Lung Cancer: Updated Results From A multiple-center real-world experience
Qingyi Zhang, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou,
China

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 166P - MRD Evaluation of Aumolertinib in EGFR Mutation-positive stage IB and stage IA2-3
NSCLC After Complete Surgical Resection: A Multicenter, Single-arm, Open-lable Study
Chao Cheng, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

13:00 - 13:00 167P - Neoadjuvant (NEO) versus perioperoperative (PERIOP) chemo-immunotherapy (CT-
ICI) according to pathological response (PR) in resectable Non Small Cell Lung Cancer
(NSCLC): an individual patient data (IPD) analysis
Antonio Nuccio, IRCCS Ospedale San Raffaele, Milan, Italy

13:00 - 13:00 168P - Surgical Outcomes for Lung Carcinoid Tumors: A 5-Year Experience from a
Portuguese Center
Catarina Pereira Moita, ULS São José - Hospital Santa Marta, Lisbon, Portugal

13:00 - 13:00 169P - THASSOS-INTL Türkiye Subset: Unveiling Treatment Patterns and Clinical
Outcomes in Resectable Early-Stage NSCLC
Ahmet Sezer, Baskent University, Adana, Türkiye

13:00 - 13:00 170P - Real world (RW) characteristics, treatment (Tx) patterns and biomarker use in
patients (pts) with early stage non-small cell lung cancer (ES NSCLC) in Greece: Results of
the retrospective INFINITY study
Sofia Agelaki, University General Hospital of Heraklion, Heraklion, Greece

13:00 - 13:00 171P - Prognostic Impact of Lymph Node Micrometastasis in T1-2a Non-small Cell Lung
Cancer
Hiroyasu Koga, Yokohama City University Graduate School of Medicine, Yokohama, Japan

13:00 - 13:00 172P - Qualitative study to identify drivers and barriers of adherence to adjuvant
osimertinib for early-stage EGFR positive non-small cell lung cancer (NSCLC)
Narjust Florez, Harvard Medical School, Boston, United States of America

13:00 - 13:00 173P - Clinical and Pathological Insights into EGFR-Mutated Early-Stage Non-Small Cell
Lung Cancer (NSCLC): Associations with Survival, PD-L1 Expression, and Second Primary
Neoplasms
Benedetta Del Rio, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, Italy

13:00 - 13:00 174P - Health-Related Quality of Life (HRQoL) assessment in trials testing Tyrosine Kinase
Inhibitors (TKI) or Immune Checkpoint Inhibitors (ICIs) in resectable Non-Small Cell Lung
Cancer (NSCLC).
Fabio Salomone, Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia,
Napoli, Italy

13:00 - 13:00 175TiP - ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised
phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant
chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC.
Sabine Schmid, Inselspital - Universitatsklinik fur Medizinische Onkologie, Bern, Switzerland

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 176TiP - Perioperative Adebrelimab Plus Chemotherapy for Resectable Non-Small Cell
Lung Cancer Harboring EGFR Mutations: A Multicenter, Phase II Trial
Gebang Wang, Liaoning Cancer Hospital & Institute, Shenyang, China

13:00 - 13:00 177TiP - Phase II Clinical Study of Adebrelimab Combined with Carboplatin, Albumin-
Bound Paclitaxel, and Recaticimab in Perioperative Treatment of Resectable NSCLC
Jinghui Wang, Beijing Chest Hospital, Capital Medical University, Beijing, China

13:00 - 13:00 178TiP - Bronchoalveolar Lavage (BAL) to Accelerate Time to Molecular Diagnosis in Early-
stage Lung Cancer (AToM-001)
Beatriz Jimenez Munarriz, Princess Margaret Cancer Centre, Toronto, Canada

13:00 - 13:00 179TiP - Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small
Cell Lung Cancer (NEOLORA)
Fan Yang, Peking University Peoples Hospital, Beijing, China, Beijing, China

13:00 - 13:00 180P - Assessment of an Artificial Intelligence (AI) solution to Support a Lung Nodule
Program
K. Adam Lee, Jupiter Medical Center, Jupiter, United States of America

13:00 - 13:00 181P - Evaluating Probe-based Confocal Laser Endomicroscopy for Lung Nodule Diagnosis:
A Comprehensive Systematic Review and Meta-analysis
Najiba Nurisma, University of Indonesia, Depok, Indonesia

13:00 - 13:00 182P - An Innovative Deep Learning Method for Automated PD-L1 Expression Assessment
in Non-Small Cell Lung Cancer
Semir Vranic, Qatar University College of Medicine, Doha, Qatar

13:00 - 13:00 183P - Development of imaging complexity biomarkers for prediction of symptomatic
radiation pneumonitis in patients with non-small cell lung cancer, focusing on underlying
lung disease
Hakyoung Kim, Korea University Guro Hospital, Seoul, Republic of Korea

13:00 - 13:00 184P - 18F-BMS-986192 PET for predicting clinical response to Immunotherapy in NSCLC: A
novel approach beyond PD-L1 immunohistochemistry.
Frank Borm, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, Netherlands

13:00 - 13:00 190P - Real-world 5-year survival outcomes with durvalumab (D) after chemoradiotherapy
(CRT) in unresectable, stage III NSCLC (urNSCLC): final data extraction from PACIFIC-R
Nicolas Girard, Institut Curie, Paris, France

13:00 - 13:00 191P - Patient-Reported versus Clinician-Reported Outcomes in Patients Undergoing

Concurrent Chemoradiotherapy and Durvalumab Maintenance for Inoperable Stage III
NSCLC: Insights from the Prospective PRECISION Study
Lukas Käsmann, LMU Klinikum der Universität München, Munich, Germany

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 192P - Differential effect of proton pump inhibitors (PPIs) and antibiotics (ATB) on clinical
outcomes from immunotherapy or placebo in patients with locally advanced,
unresectable NSCLC who have not progressed following chemoradiation therapy (cCTRT):
A post-hoc analysis of the PACIFIC trial
Leonardo Brunetti, Policlinico Universitario Campus Bio-Medico, Rome, Italy

13:00 - 13:00 193P - Association of Effective Dose to Immune Cells with Outcomes after Definitive
Chemoradiotherapy and Durvalumab in Non-Small Cell Lung Cancer: A Multi-Center Study
Ari Raphael, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, Israel

13:00 - 13:00 194P - Durvalumab prolongs overall survival whereas radiation dose escalation >66 Gy
improves long-term local control in unresectable NSCLC stage III: updated analysis of the
Austrian radio-oncological lung cancer study association registry (ALLSTAR)
Franz Zehentmayr, Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria

13:00 - 13:00 195P - REAL-WORLD STUDY OF PATIENTS WITH UNRESECTABLE STAGE III NON-SMALL CELL
LUNG CANCER TREATED WITH CHEMORADIOTHERAPY FOLLOWED BY DURVALUMAB: RA-
PACIFIC.
Luis Basbus, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

13:00 - 13:00 196P - 5-year survival and safety of stereotactic ablative radiotherapy in unresectable
locally advanced non-small cell lung cancer patients unfit for concurrent radio-
chemotherapy: focus on patterns of local recurrence from the START-NEW-ERA non-
randomized phase II trial
Fabio Arcidiacono, Radiotherapy Oncology Centre "S.Maria" Hospital, Terni, Italy

13:00 - 13:00 197P - Efficacy and Safety of Induction Chemo-Immunotherapy in Unresectable Stage III
Non-Small Cell Lung Cancer: A Real-World Multicenter Retrospective Study
Wenlu Chen, Shanxi Provincial Cancer Hospital, Taiyuan, China

13:00 - 13:00 198P - Progression Patterns and Survival Outcomes in Patients with Locally Advanced
NSCLC After Chemo-Radiotherapy and Durvalumab: Insights into Post-Progression
Strategies from a Single Institution
Rita Leporati, Modena University Hospital, Modena, Italy, Modena, Italy

13:00 - 13:00 199P - Toxicity profiles of definitive chemoradiation with and without immunotherapy
Salma Jabbour, Rutgers Cancer Institute of New Jersey, New Brunswick, United States of America

13:00 - 13:00 200P - The Impact of COVID 19 Infection in Patients Undergoing Definitive Chemoradiation
for Locally Advanced Lung Cancer
Bryce Comstock, Mayo Clinic - Rochester, Rochester, United States of America

13:00 - 13:00 201P - Patient-reported outcomes (PROs) from the LAURA study: Osimertinib (osi) in
patients with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung
cancer (NSCLC) without progression after definitive chemoradiotherapy (CRT)
Edurne Arriola Aperribay, Hospital del Mar-CIBERONC, Barcelona, Spain

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 202P - Durvalumab after Definitive Chemoradiation (dCRT) in Non-small cell lung cancer
(NSCLC) patients with Actionable Driver Mutations
Jason C S, Queen Elizabeth Hospital, Kowloon, Hong Kong SAR, China

13:00 - 13:00 203P - Immunotherapy improves clinical outcome in KRAS mutated patients with
unresectable NSCLC stage III: a subcohort analysis of the Austrian radio-oncological lung
cancer study association regristry (ALLSTAR)
Franz Zehentmayr, Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria

13:00 - 13:00 204P - Localised non-small cell lung cancer: patient characteristics and radical
radiotherapy outcomes according to KRAS mutation status.
Ana Sofia Parreira, The Christie NHS Foundation Trust, Manchester, United Kingdom

13:00 - 13:00 205P - EGFR-TKI Combined with Chemotherapy versus EGFR-TKI Alone for locally advanced
EGFR-mutant NSCLC: A Real-World Study
Yu Jiang, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

13:00 - 13:00 206P - Radiotherapy-Induced Atrial Fibrillation in Lung Cancer: Should Pulmonary Veins
Be Considered as Organs at Risk?
Mouna Ben Rejeb, Hopital Abderrahmen Mami de Pneumo-Phistiologie, Ariana, Tunisia

13:00 - 13:00 207P - Phase I Study of Reirradiation (ReRT) with NBTXR3 for Inoperable Locoregional
Recurrent Non-Small Cell Lung Cancer (NSCLC)
Saumil Gandhi, MD Anderson Cancer Center, Houston, United States of America

13:00 - 13:00 208P - Pathological response after neoadjuvant chemotherapy (chemo) and nivolumab
(NIVO) in resectable non-small cell lung cancer (NSCLC): initial results from a french multi-
center real-world (rw) retrospective study
Francesca Lucibello, Institut Curie, Paris, France

13:00 - 13:00 209P - Four-Year Outcomes with Perioperative Toripalimab plus Chemotherapy in
Resectable Stage III Non-Small Cell Lung Cancer (NeoTAP01 Study)
Yuheng Zhou, Sun Yat-Sen University Cancer Center, Guangzhou, China

13:00 - 13:00 210P - Prognostic Value of Minimal Residual Disease in the NADIM II Trial
Roberto Serna-Blasco, University Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain

13:00 - 13:00 211P - Five-year Survival Outcomes from PIT-2: S-1 Plus Cisplatin with Concurrent
Radiotherapy Followed by Surgery in Stage IIIA (N2) Lung Squamous Cell Carcinoma
Kazuya Takamochi, Juntendo University International Center (JUIC), Tokyo, Japan

13:00 - 13:00 212P - Recurrence in Patients with Non-Small Cell Lung Cancer Achieving Pathological
Complete Response after Neoadjuvant Treatment
Yuechun Lin, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 213P - Surgical Outcomes After Neoadjuvant Chemo-Immunotherapy for NSCLC: a
Systematic Review and Meta-Analysis
Claudia Bardoni, Università degli Studi di Milano, Milan, Italy

13:00 - 13:00 214P - Refining Central Lung Cancer Surgery: Uniportal Video-Assisted Thoracic Surgery
with Three-Dimensional Vascular Mapping After Neoadjuvant Chemoimmunotherapy
Zhilin Luo, The Third Affiliated Hospital of Chongqing Medical University (CQMU), Chongqing,
China

13:00 - 13:00 215P - Safety and Necessity of Mediastinal Lymph Nodes Dissection Omission Following
Nodal Clearance with Neoadjuvant Immunochemotherapy in cN0/N1 Non-Small Cell Lung
Cancer
Yuheng Zhou, Sun Yat-Sen University Cancer Center, Guangzhou, China

13:00 - 13:00 216P - Prognostic Impacts of Skip Metastasis in N2a and N2b Subgroups in Non-Small Cell
Lung Cancer?Insights from a Large Cohort
Shenhua Liang, Sun Yat-Sen University Cancer Center, Guangzhou, China

13:00 - 13:00 217P - Survival Outcomes in Patients with Lung Cancer and Major Vessel Invasion
Undergoing Curative Intent Radiotherapy
Gerard Gurumurthy, The University of Manchester, Manchester, United Kingdom

13:00 - 13:00 218P - Induction triplet chemotherapy for Stage 3 non-small cell lung cancer
Mustafa Erman, Hacettepe University, Ankara, Türkiye

13:00 - 13:00 219P - Real-World Outcomes of Lung Resections After Neoadjuvant Chemo-
Immunotherapy for Resectable NSCLC: A Single-Center Experience
Filippo Tommaso Gallina, IRCCS Regina Elena National Cancer Institute (IRE), Rome, Italy

13:00 - 13:00 220P - Surgical Outcomes in the Treatment of Stage IIIA and IIIB Non-Small Cell Lung
Carcinoma: 7-Year Analysis from a Portuguese Center
Catarina Pereira Moita, ULS São José - Hospital Santa Marta, Lisbon, Portugal

13:00 - 13:00 221P - Reasons for discontinuation of adjuvant therapy in N2 Non-small lung cancer
(NSCLC), a retrospective, real world cohort study
Rahel Decker, Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Germany

13:00 - 13:00 222P - Adjuvant platinum-based chemotherapy role in stage II-IIIA EGFR-mutated lung
cancer: an IPD meta-analysis of phase III randomized controlled trial
Riccardo Tajè, IRCCS Regina Elena National Cancer Institute (IRE), Rome, Italy

13:00 - 13:00 223P - Adjuvant novel tyrosine kinase inhibitors with or without platinum-based
chemotherapy for resectable oncogene-addicted NSCLC: an IPD meta-analysis of phase III
randomized clinical trials
Riccardo Tajè, IRCCS Regina Elena National Cancer Institute (IRE), Rome, Italy

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 224P - Predictive Value of FDG PET/CT Parameters and T Cell Subsets in Stage II/III Non-
small Cell Lung Cancer with Neoadjuvant Immunotherapy
Eun Seong Lee, Korea University Guro Hospital, Seoul, Republic of Korea

13:00 - 13:00 225P - Circulating Tumor DNA as a Prognostic Biomarker in Unresectable Locally Advanced
NSCLC
Nil Navarro-Gorro, Hospital del Mar - Parc de Salut Mar, Barcelona, Spain

13:00 - 13:00 226P - Real world patient characteristics and TREAtment Patterns for stage III in NSCLC in
FRance - TREAP
Christos Chouaid, Service de Pneumologie, CHI Créteil, Créteil, France

13:00 - 13:00 227P - Prognostic Significance of LIPI Score at Diagnosis in Stage 3 Non-Small Cell Lung
Cancer: A Retrospective Study
Engin Kavak, Ankara University Medical School - Cebeci Hastaneleri Tibbi Onkoloji, Ankara,
Türkiye

13:00 - 13:00 228P - Type VII Collagen Enhances Matrix Viscoelasticity and Modulates Immune Response
in Advanced Lung Adenocarcinoma
Pengxu Kong, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou,
China

13:00 - 13:00 230P - A retrospective analysis on patterns of surveillance after curative intent treatment
for unresectable stage III Non-Small Cell Lung Cancer (NSCLC)
Marie-Frédérique D'Amours, BC Cancer Agency - Vancouver, Vancouver, Canada

13:00 - 13:00 231P - Prognostic Factors for Survival in Unresectable Stage III Non-Small Cell Lung Cancer
(NSCLC) Receiving Chemoradiotherapy (CRT)
Jikai Zhou, Univerity of Maastricht, Maastricht, Netherlands

13:00 - 13:00 232P - How Socioeconomic Status (SES) Shapes Lung Adenocarcinoma Diagnosis and
Survival in Brazil: A Population-Based Analysis
Fernanda Malucelli Favorito, Faculdade de Ciencias Medicas da Santa Casa de Sao Paulo, Sao
Paulo, Brazil

13:00 - 13:00 233P - Chemo-immunotherapy for borderline resectable and unresectable NSCLC
Federico Cappuzzo, IRCCS Regina Elena National Cancer Institute, Rome, Italy

13:00 - 13:00 234P - Compliance with Adjuvant, Neoadjuvant, and Perioperative Immunotherapy-Based
Treatment Protocols in Patients with Resectable Non-Small-Cell Lung Cancer: A Systematic
Review and Meta-Analysis
Francesco Guerrera, Università degli Studi di Torino, Torino, Italy

13:00 - 13:00 235P - A Stage III, non-small cell lung Cancer (NSCLC) Multidisciplinary meeting (MDT) to
increase access to concurrent chemo-radiation in a Northern UK cancer centre.
Alastair Greystoke, Newcastle University, Newcastle upon Tyne, United Kingdom

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 236P - Prospective trial of immuno-(chemo)therapy prior to resection, definitive chemo-
radiotherapy, or palliative therapy in patients with oligometastatic non-small cell lung
cancer (KOMPASSneo)
Eun Ji Rhee, Klinikum Esslingen, Esslingen am Neckar, Germany

13:00 - 13:00 237P - 125I particles implantation is an effective therapy for oligo-progression during
immunotherapy.
Yu Yao, First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China

13:00 - 13:00 238TiP - An Update on the CONCORDE study: A Phase Ib Platform Study of DNA Damage
Repair Inhibitors (DDRIs) in Combination With Conventional Radiotherapy in NSCLC
Ashley Horne, The Christie NHS Foundation Trust, Manchester, United Kingdom

13:00 - 13:00 240P - Real world toxicity data for the use of ipilimumab plus nivolumab in malignant
mesothelioma across 11 UK centres
Harriet Mcgrath, The Royal Marsden Hospital (Sutton), Sutton, United Kingdom

13:00 - 13:00 241P - Real-world evidence of the impact of immunotherapy (ICI) on myocarditis in p with
pleural mesothelioma (PM)
Susana Cedres Perez, Vall d'Hebron University Hospital, Barcelona, Spain

13:00 - 13:00 242P - SAKK 17/18 ORIGIN trial: Efficacy and safety from a multicentre phase II trial of
gemcitabine and atezolizumab in pretreated patients with pleural mesothelioma
Angelica Rigutto, University of Fribourg, Fribourg, Switzerland

13:00 - 13:00 243P - Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer
Harboring HRR Gene Mutations: Updated analysis from the UNITO-001 Phase II Trial
Giovanni Farinea, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, Italy

13:00 - 13:00 244P - Laboratory parameters associated with the survival in patients with malignant
pleural mesothelioma on maintenance gemcitabine
Mohamed Emam, NCI - National Cancer Institute, Cairo, Egypt

13:00 - 13:00 245P - The Predictive and Prognostic Value of T- and B-cell Transcriptomic Signatures for
Clinical Response to Immune Checkpoint Blockade in Pleural Mesothelioma
Jasper Van Genugten, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, Netherlands

13:00 - 13:00 246P - Optimizing Immune Checkpoint Blockade in Pleural Mesothelioma by Targeting
Immune Evasion: A Systems Biology Approach
Jasper Van Genugten, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, Netherlands

13:00 - 13:00 247P - The adenosine pathway is an actionable multitarget for Mesothelioma (MMe)
Luciano Mutti, UNIVAQ - University of L'Aquila, Coppito, Italy

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 248TiP - Phase II study of pembrolizumab in combination with cisplatin or carboplatin and
pemetrexed as induction chemoimmunotherapy in resectable epithelioid and biphasic
pleural mesothelioma (CHIMERA study)
Giulia Pasello, University of Padua/Istituto Oncologico Veneto IRCCS, Padova, Italy

13:00 - 13:00 249P - Pattern of Brain Metastases and Survival in Lung Adenocarcinoma with KRAS or
EFGR mutation
Martin Faehling, Klinikum Esslingen, Esslingen am Neckar, Germany

13:00 - 13:00 250P - Prognostic Insights into Lung Adenocarcinoma with Peripheral Nervous System
Metastases: Spotlight on EGFR Mutation Status
Samah Al-Omari, Jordan University of Science and Technology, Irbid, Jordan

13:00 - 13:00 251P - Assessing Treatment Outcomes in Metastatic NSCLC with Rare EGFR Mutations
Shawn Ellis, Royal Berkshire Hospital, Reading, United Kingdom

13:00 - 13:00 252P - Surgical and Pathology Outcome of a Randomized, Phase II Trial of EGFR TKI with
Primary Tumor Resection for EGFR-Mutant Metastatic NSCLC Patients: Feasibility
Evaluation
Pei-Hsing Chen, National Taiwan University Hospital, Taipei City, Taiwan

13:00 - 13:00 253P - Surgical vs Non-surgical management of non-small cell lung cancer with brain
metastases
Dema Albataineh, IAU - The University of Jordan, Amman, Jordan

13:00 - 13:00 254P - Serial monitoring of cerebrospinal fluid in lung cancer patients with brain
metastases via the ommaya reservoir as a predictive indicator of therapeutic efficacy and
clinical prognosis
Shen Cun Fang, Nanjing Chest Hospital - Medical School of Southeast University, Nanjing, China

13:00 - 13:00 255P - NBTXR3 activated by SBRT in combination with nivolumab or pembrolizumab for
the treatment of patients with lung metastases from NSCLC or other solid tumors in the
phase I trial Study 1100
Colette Shen, UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel
Hill, United States of America

13:00 - 13:00 256P - 2-year survival outcomes of Atezolizumab Plus Bevacizumab as First-line Treatment
for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor
Mutation Burden: TELMA trial final report
Mariano Provencio Pulla, University Hospital Puerta de Hierro Majadahonda, Majadahonda,
Spain

13:00 - 13:00 257P - Stereotactic radiotherapy for oligometastatic mediastinal lymph-nodes: a

multicentre retrospective experience
Francesco Cuccia, ARNAS Civico Hospital, Palermo, Italy

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 258P - Pan-cancer analyses reveal tissue-type-specific intracellular bacteria in lung
metastatic cancer
Haiming Chen, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital,
Fuzhou, China

13:00 - 13:00 259P - Association of Gut Microbiome with Radiotherapy Efficacy in Lung Cancer Patients
with Brain Metastases
Xia Youyou, The First People's Hospital of Lianyungang/ Lianyungang Clinical College of Nanjing,
Liangyungang city, China

13:00 - 13:00 260P - Exploring the Inner and outer Realms of young lung cancer - A decade of experience
Raveena Gullapalli, Basavatarakam Indo American Cancer Hospital & Research Institute,
Hyderabad, India

13:00 - 13:00 261TiP - A single arm phase 2 study of PCSK9 inhibitor, alirocumab, and PD-1 inhibitor,
cemiplimab, in advanced immuno-refractory metastatic non-small cell lung cancer
(TOP2201).
Eziafa Oduah, Duke Cancer Center - Duke University Medical Center, Durham, United States of
America

13:00 - 13:00 264P - Innovative Portable Breathomic Device For Early Non-Invasive Differentiation Of
Benign And Malignant Lung Nodules
Hengrui Liang, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

13:00 - 13:00 265P - Association Between Digestive System Diseases and Lung Cancer Risk: A
Comprehensive Evaluation based on UK Biobank
Yi Feng, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

13:00 - 13:00 266P - Association Between Serum Branched-Chain Amino Acids and Cancer Risk: Findings
from a Prospective Cohort Study in the UK Biobank
Yi Feng, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

13:00 - 13:00 267P - Personality profiling in patients with thoracic neoplasia: a different look to change
our mindset
Elisa Roca, Ospedale P. Pederzoli Casa di Cura Privata Spa, Peschiera Del Garda, Italy

13:00 - 13:00 268P - Prognostic value of systemic immune inflammation index in squamous cell lung
cancer
Fadil Umihani?, Istanbul University-Cerrahpasa - Faculty of Medicine, Istanbul, Türkiye

13:00 - 13:00 269P - BREATHING EXERCISIZE IMPACT ON QUALITIY OF LIFE WITH LUNG CANCER
PATIENTS
Bruno Ezbegovic, University Hospital Center Osijek, Osijek, Croatia

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 270P - Machine Learning-Based Prediction of Survival Prognosis for Treated NSCLC
Patients: Insights from Finnish Real-World Data
Ville Koistinen, Kymenlaakso Central Hospital, Kotka, Finland

13:00 - 13:00 271P - WHEN CANCER AND INFECTION COLLIDE: MORTALITY TRENDS IN PNEUMONIA AND
LUNG CANCER (1999-2020)
Mahmoud Elbadrawy, Northumbria Healthcare NHS Trust, Newcastle Upon Tyne, United
Kingdom

13:00 - 13:00 272P - Lifestyle and nutritional assessment among lung cancer screening participants
Massimiliano Cani, Università Degli Studi Di Torino - Orbassano, Orbassano, Italy

13:00 - 13:00 273P - Effect of lung cancer screening, smoking cessation and cessation smartphone
application to health-related quality of life
Sanna Iivanainen, OYS - Oulu University Hospital, Oulu, Finland

13:00 - 13:00 274P - AI/ML-Based Lung Cancer Detection and Characterization for Lung Cancer
Screening: Results from the REALITY Study on Early-Stage Lung Cancer
Raymond Osarogiagbon, Baptist Memorial Hospital, Memphis, United States of America

13:00 - 13:00 275P - Multiomic biomarkers to predict and intercept inflammation to lung cancer
transition
Marine Fidelle, Institut Gustave Roussy, Villejuif, France

13:00 - 13:00 276P - A multicenter exhaled breath metabolomics lung cancer screening model based on
PTR-TOF MS
Chen Huang, West China School of Medicine/West China Hospital of Sichuan University,
Chengdu, China

13:00 - 13:00 277P - Preliminary results of LC-SHIELD study (Lung Cancer Screening in HIgh risk non-
smokErs with artificial inteLligence Device)
Siu Ching Li, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, Hong Kong
SAR, China

13:00 - 13:00 278P - Dynamic Machine Learning for Early Lung Cancer Identification Using Longitudinal
Clinical and Laboratory Data
Ye Wenjun, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

13:00 - 13:00 279P - Study on screening and diagnosis model of smokers based on PTR-TOF-MS
Chen Huang, West China School of Medicine/West China Hospital of Sichuan University,
Chengdu, China

13:00 - 13:00 280P - The impact and uptake of a framework to support the implementation of low-dose
computed tomography screening for lung cancer
Zhandos Amankulov, Kazakh Research Institute of Oncology and Radiology-KazIOR, Almaty,
Kazakhstan

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 281P - App-based Acquisition of Patient-reported Data for Real-world Insights into NSCLC
Patient Journeys
Carolin Gross-Ophoff-Mueller, Kliniken der Stadt Köln gGmbH, Köln, Germany

13:00 - 13:00 282P - Early detection of stage I/II NSCLC by immunoassay of crosslinked plasma cell fee
nucleosomes
Jake Micallef, Belgian Volition SPRL, Isnes, Belgium

13:00 - 13:00 283P - I3LUNG AI-Driven Cough Analysis: A Novel Tool for Non-Small Cell Lung Cancer
Detection
Arsela Prelaj, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

13:00 - 13:00 284P - Results of systematic enrolment of participants into regional lung cancer screening
pilot study in Estonia
Tanel Laisaar, Tartu University Hospital, Tartu, Estonia

13:00 - 13:00 285P - Lung and bronchus cancer incidence and mortality trends in Jordan and USA: an
epidemiological study
Omar Daas, IAU - The University of Jordan, Amman, Jordan

13:00 - 13:00 286P - Overcoming Biomarker Testing Barriers for Non-Small Cell Lung Cancer (NSCLC):
OncoCollective Insights into Improving Patient Outcomes in Europe (EU)
Arnaud Bayle, Institut Gustave Roussy, Villejuif, France

13:00 - 13:00 287P - From Reactive to Proactive lung cancer service delivery model: implementation of
Rapid Access Lung Lesion Clinic (RALLC) and its clinical impact in a large, regional cancer
centre in Australia.
Wasek Faisal, UFS Medical Centres, Ballarat, Australia

13:00 - 13:00 288P - Non-metastatic adenosquamous lung carcinoma disparities by ethnicity and
income
Inae Park, Montefiore Medical Center - Moses Campus, Bronx, United States of America

13:00 - 13:00 289P - Early Lung Cancer Detection Using Artificial Intelligence on Chest X-rays: The
Budget Impact of Implementing Incidental Pulmonary Nodule Detection
Bert Sloof, UMCG - University Medical Center Groningen, Groningen, Netherlands

13:00 - 13:00 290P - Development of a Smoking-Induced Lung Cancer Model Using 3D Spheroid Culture
and Microfluidic Chips
Sang Haak Lee, The Catholic University of Korea - College of Medicine, Seoul, Republic of Korea

13:00 - 13:00 291P - Preliminary results of cytisine therapy and tobacco cessation program in the Italian
Lung Cancer Screening Program
Massimiliano Cani, Università Degli Studi Di Torino - Orbassano, Orbassano, Italy

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 292P - Using liquid biopsy in early lung cancer diagnosis: A systematic review of health
economic analyses and budget impact analysis for the UK NHS
Ee Phui Kew, Guys and St Thomas' NHS Foundation Trust, London, United Kingdom

13:00 - 13:00 293P - 22 Years of Cardiovascular Mortality in U.S. Adults with Lung Cancer: Insights from
National CDC Data
Munikaverappa Anjanappa Mukesh, South Tyneside District General Hospital, South Shields,
United Kingdom

13:00 - 13:00 294P - Innovative liquid biopsy for lung cancer early detection - A proof of concept study
Abed Agbarya, Bnai Zion Medical Center, Haifa, Israel

13:00 - 13:00 295P - Analytical and Clinical Validation of a Cost-Effective ctDNA-Based Assay for Lung
Cancer Detection
Chi Nguyen, Medical Genetics Institute, Ho Chi Minh City, Vietnam

13:00 - 13:00 296P - Circulating Progastrin (hPG80): A versatile blood-based biomarker for all stages of
Non-Small Cell Lung Cancer management
Eider Azkona Uribelarrea, Osakidetza, Vitoria-Gasteiz, Spain

13:00 - 13:00 298P - Validation of the Lung Immune Prognostic Index (LIPI) in Extensive-Stage small cell
lung cancer (esSCLC): Post Hoc Analysis of the CASPIAN and IMpower133 Phase 3 Trials
Edouard Auclin, HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, France

13:00 - 13:00 299P - First-line (1L) durvalumab (D) + platinum-etoposide (EP) in extensive-stage SCLC
(ES-SCLC): Final results and exploratory biomarker analyses from LUMINANCE
Natasha Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto,
Canada

13:00 - 13:00 300P - CT-based intratumoral and peritumoral radiometric characteristics accurately
predict the risk of distant metastasis in small cell lung cancer
Ran Wang, The First Affiliated Hospital of Anhui Medical University, Hefei, China

13:00 - 13:00 301P - Baseline CT radiomics predict response to chemotherapy and

chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Mohammadhadi Khorrami, Emory University, Atlanta, United States of America

13:00 - 13:00 302P - Phase 2 study of the efficacy and safety of BNT327/PM8002 plus systemic
chemotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC)
Ying Cheng, Jilin Cancer Hospital, Changchun, China

13:00 - 13:00 303P - Identifying Novel Prognostic Markers in Small Cell Lung Cancer Through
Comprehensive In-silico Analysis
Vivien Teglas, Semmelweis University, Budapest, Hungary

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 304P - Prognostic markers and Molecular Insights: Navigating SCLC with Liver Metastasis
Jing Ding, University of Electronic Science and Technology of China, Chengdu, China

13:00 - 13:00 305P - Liver Metastases Compromise the Benefit of Adding Anti-PD-L1 Therapy to First-
Line Chemotherapy in Extensive-Stage Small Cell Lung Cancer (esSCLC): A Post Hoc
Analysis of the CASPIAN and IMpower133 Trials
Edouard Auclin, HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, France

13:00 - 13:00 306P - The Effect of Initial Metastatic Site on Survival in Extensive-Stage Small Cell Lung
Cancer
Hatice Topal, Istanbul University-Cerrahpasa - Faculty of Medicine, Istanbul, Türkiye

13:00 - 13:00 307P - Real-world overall survival among patients with extensive-stage SCLC treated with
first-line chemoimmunotherapy in the US
Xiuning Le, Department of Thoracic Head and Neck Medical Oncology, The University of Texas
MD Anderson Cancer Center, Houston, United States of America

13:00 - 13:00 308P - Real-world outcomes in extensive-stage small cell lung cancer treated with first-line
serplulimab: The nationwide observational ASTRUM-005R study
Lin Wu, Hunan Cancer Hospital, Changsha, China

13:00 - 13:00 309P - Long-term survivors with extensive-stage small-cell lung cancer treated with first-
line durvalumab plus carboplatin and etoposide: the CANTABRICO trial
Maria Dolores Isla Casado, Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain

13:00 - 13:00 310P - Final overall survival (OS) of surufatinib plus PD-1/PD-L1 antibodies as
maintenance therapy following first line (1L) platinum-based chemotherapy (Chemo) plus
PD-1/PD-L1 antibodies in patients (pts) with extensive-stage small cell lung cancer (ES-
SCLC)
Yi Hu, General Hospital of Chinese People’s Liberation Army, Beijing, China

13:00 - 13:00 311P - Evaluation of durvalumab real-world use and effectiveness in first line extensive-
stage small-cell lung cancer: primary results of the ARSENAL study
Jean Bernard Auliac, CHI - Centre Hospitalier Intercommunal de Créteil, Créteil, France

13:00 - 13:00 312P - Correlation between immune-related adverse events (irAEs) and Survival Outcomes
in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) patients (pts) treated with chemo-
immunotherapy (CT-IO).
Federico Monaca, The Christie NHS Foundation Trust, Manchester, United Kingdom

13:00 - 13:00 313P - Baseline PD-L1 expression in circulating neutrophils predicts immune-related
adverse events (irAEs) in patients with extensive-stage small-cell lung cancer from
CANTABRICO trial
Andrés Barba Joaquín, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 314P - Predictors of long-term response and survival in patients with extensive stage
small cell lung cancer (ES-SCLC) receiving atezolizumab plus chemotherapy in a real-world
setting (IFCT-1905 CLINATEZO)
Lionel Falchero, L'Hopital Nord Ouest - Villefranche-Sur-Saone, Villefranche-Sur-Saone, France

13:00 - 13:00 315P - Patient-reported outcomes from CANTABRICO: durvalumab plus platinum-
etoposide in first-line treatment of extensive-stage small cell lung cancer.
Maria Dolores Isla Casado, Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain

13:00 - 13:00 316P - Predictive power of microenvironment YAP-1 and CD31 expression and potential
use of EPSILON score in Small Cell Lung Cancer (SCLC) treated with chemoimmunotherapy
Elisa Roca, Ospedale P. Pederzoli Casa di Cura Privata Spa, Peschiera Del Garda, Italy

13:00 - 13:00 317P - Impact of Induction Chemotherapy Cycles on the Efficacy of First-Line Atezolizumab
Combined with Chemotherapy in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Mengxing You, Chinese Academy of Medical Sciences and Peking Union Medical College -
National Cancer Center, Beijing, China

13:00 - 13:00 318P - Impact of Prophylactic Cranial Irradiation on Survival in Extensive-Stage Small Cell
Lung Cancer Receiving First-Line Chemoimmunotherapy: A Propensity Score-Matched
Study
Yun Fan, Zhejiang Cancer Hospital, Hangzhou, China

13:00 - 13:00 319P - Basal PD-L1 expression on leukocyte subpopulations in patients with extensive-
stage small cell lung cancer treated with first-line atezolizumab plus platinum and
etoposide
Judit Sanz Beltran, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

13:00 - 13:00 320P - Lysine-specific Demethylase 1A (LSD1) inhibition attenuates phenotypic transition
and delays the tumor relapse to radioimmunotherapy in small cell lung cancer
Hui Wang, West China School of Medicine/West China Hospital of Sichuan University, Chengdu,
China

13:00 - 13:00 321P - Impact of DNA Damage Response Score on Immune Markers in Small Cell Lung
Cancer: Insights from NGS Profiling and Transcriptomic Analysis.
Caterina De Rosa, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy

13:00 - 13:00 322P - Small Extracellular Vesicle miRNAs as Predictive Biomarkers for
Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
Wei Zhang, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, shanghai, China

13:00 - 13:00 323P - Molecular subtypes and their correlation to clinical outcomes in a real-world
analysis of patients with extensive stage small cell lung cancer (ES-SCLC) treated with
first-line chemo-immunotherapy
Núria Zellweger, Universitätsspital Basel, Basel, Switzerland

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 324P - Survival Analysis of the Impact of First-Line Chemotherapy Dose Intensity in
Patients with Extensive-Stage Small Cell Lung Cancer
Adrian Sanchez Vegas, Hospital Universitario Virgen de Valme, Seville, Spain

13:00 - 13:00 325P - Identifying Novel Somatic Mutations in SCLC Through Next Generation Sequencing
Pragya Kashyap, IITJ - Indian Institute of Technology Jodhpur, Jodhpur, India

13:00 - 13:00 326P - Synergistic Interaction Between Extracellular Matrix and Epithelial-Mesenchymal
Transition Factors Drives Invasive and Metastatic Phenotypes in Pulmonary
Neuroendocrine Tumors
Tabatha Prieto, University of Sao Paulo - Faculty of Medicine, Sao Paulo, Brazil

13:00 - 13:00 327P - Genetic alterations of Circulating Tumor Cells (CTCs) isolated from liquid biopsies
of Small Cell Lung Cancer (SCLC) at the time of diagnosis
Laetitia Martinetti, INSERM U1242 - Oncogenesis Stress Signaling, RENNES, France

13:00 - 13:00 328P - The Prognostic Analysis and Model Establishment of Central and Peripheral Small
Cell Lung Cancer
Yu Yao, First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China

13:00 - 13:00 329P - Intracranial efficacy of YL201, a novel B7-H3-targeting antibody-drug conjugate
(ADC), in patients (pts) with small cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC)
Hongyun Zhao, Sun Yat-sen University Cancer Center, Guangzhou, China

13:00 - 13:00 330P - A comparison of tarlatamab with real-world physicians’ choice of therapies
in patients with previously treated small cell lung cancer
Umit Tapan, Boston University Medical Center-Solomont Center for Hematology and Oncology,
Boston, United States of America

13:00 - 13:00 331P - A single-arm, open-label, prospective, single-center clinical study on the treatment
of patinum-resistant relapse small cell lung cancer with nab-paclitaxel combined with
apatinib
Xue Yang, Peking niversity Cancaer Hospital&Institute, Beijing, China

13:00 - 13:00 332P - Updated phase II efficacy and safety results of BNT327/PM8002 combined with
paclitaxel as second-line (2L) therapy in small cell lung cancer (SCLC)
Ying Cheng, Jilin Cancer Hospital, Changchun, China

13:00 - 13:00 333P - Safety and effectiveness of adebrelimab as second- or later-line treatment in
extensive-stage small-cell lung cancer: a prospective, real-world study
Xiaoli Liu, Shandong University - Cheeloo College of Medicine, Qingdao, China

13:00 - 13:00 334P - Outcomes According to Dosimetric Factors: A Secondary Analysis of CALGB 30610
(Alliance)/RTOG 0538 (NRG).
Michael Mix, SUNY Upstate Medical University, Syracuse, United States of America

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 335P - Time until treatment, treatment time and outcomes of chemoradiotherapy (CRT) in
limited stage (LS) small cell lung cancer (SCLC)
Miriam Grønberg, University of Bergen, Bergen, Norway

13:00 - 13:00 336P - Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer
(LS-SCLC): ADRIATIC China subgroup analysis
Zhengfei Zhu, Fudan University Shanghai Cancer Center, Shanghai, China

13:00 - 13:00 337P - Safety and Effectiveness of hyper-fractionated Simultaneous Integrated Boost in
Definitive Chemoradiation for Limited-Stage Small Cell Lung Cancer
Wenqiang Guan, Zigong Fourth People's Hospital, Zigong, China

13:00 - 13:00 338P - Preoperative immunochemotherapy versus chemotherapy for patients with stage I-
IIIB small-cell lung cancer
Jiacong Liu, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou,
China

13:00 - 13:00 339P - A Retrospective Real-World Study of Neoadjuvant Chemotherapy in Patients with
Resectable Small-Cell Lung Cancer
Wengang Zhang, Shanghai Pulmonary Hospital, Shanghai, China

13:00 - 13:00 340P - Clinical characteristics and survival outcomes in stage I-II small cell lung cancer
(SCLC) patients (pts)
Marina Puchinskaya, Kravira Medical Centre, Minsk, Belarus

13:00 - 13:00 341P - Efficacy of Tumor Treating Fields (TTFields) in preclinical models of small cell lung
carcinoma (SCLC)
Uri Weinberg, Novocure Israel, Haifa, Israel

13:00 - 13:00 342TiP - The PESGA Trial: A prospective, open-label, single-arm, phase II study to evaluate
first line therapy for ES-SCLC patients, treated by induction
carboplatin/etoposide/pembrolizumab followed by maintenance of pembrolizumab/
sacituzumab govitecan
Laila Roisman, Shaare Zedek Medical Center, Jerusalem, Israel

13:00 - 13:00 343TiP - Maintenance Therapy with Fuzuloparib plus Adebrelimab for ES-SCLC after First-
Line Induction with Fuzuloparib plus Adebrelimab and Chemotherapy: A Prospective,
Single-Arm, Phase II Clinical Study
Huiru Xu, Shanxi Bethune Hospital, Taiyuan, China

13:00 - 13:00 344TiP - Adebrelimab plus apatinib for maintenance treatment of extensive-stage small
cell lung cancer after first-line induction with adebrelimab plus chemotherapy
(CLOG2402-ADAPT): a multi-center, single-arm, phase 2 clinical trial
Lingyun Zhang, The First Hospital of China Medical University, Shenyang, China

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 345TiP - A Phase 1 dose escalation/expansion study of GSK5764227 (GSK’227), a B7-
homologue 3 (B7-H3) protein-targeted antibody-drug conjugate (ADC), in combination with
standard of care (SoC), in patients with advanced solid tumours, including lung cancers
Hye Ryun Kim, Yonsei Cancer Center Yonsei University, Seoul, Republic of Korea

13:00 - 13:00 346P - Multi-omics approach to identify factors underlying antibiotics (ABX)-mediated
immunosuppression in a prospective trial of cancer immunotherapy
Carolina Alves Costa Silva, Institut Gustave Roussy, Villejuif, France

13:00 - 13:00 347P - AI Multimodal Tool Highlights Host and Ghost Biomarkers for Guiding
Immunotherapy Decisions in Clinical Practice
Vanja Miskovic, Politecnico di Milano, Milan, Italy

13:00 - 13:00 348P - Pulsed High-Dose Fractionated Radiotherapy Combined with Enhanced
Immunotherapy in the Treatment of Driver Gene-Negative Advanced Non-small-cell Lung
Cancer: A Clinical Study
Chuanwang Miao, Shandong Cancer Hospital and Institute, Shandong First Medical University
and Shandong Academy, Jinan, China

13:00 - 13:00 349P - An immune checkpoint inhibitor response score (ICIRS) for Non-Small Cell Lung
Cancer treatment
Guillermo Suay Montagud, Hospital Universitari i Politècnic La Fe, Valencia, Spain

13:00 - 13:00 350P - Spatial and single-cell transcriptomics to characterize T/B cell immune structures
and neighborhood stromal components associated to immunotherapy response in Non-
Small Cell Lung Cancer
Nicla Porciello, IRCCS Regina Elena National Cancer Institute, Roma, Italy

13:00 - 13:00 351P - The Application of Peripheral Blood Immune Profiling in Personalized Treatment of
Advanced Lung Cancer: A Nomogram Approach
Chuanwang Miao, Shandong Cancer Hospital and Institute, Shandong First Medical University
and Shandong Academy, Jinan, China

13:00 - 13:00 352P - Biomarkers of immunotherapy response in Non-Small-Cell Lung Cancer: Microbiota
and Short-Chain Fatty Acids
Alba Moratiel Pellitero, Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain

13:00 - 13:00 353P - Gene expression analysis of PD-1 and PD-L1 in peripheral blood mononuclear cells
(PBMCs) in non-small cell lung cancer (NSCLC) patients: Association with KRAS mutation
status and patient outcomes.
Sofia Agelaki, University General Hospital of Heraklion, Heraklion, Greece

13:00 - 13:00 354P - Monocyte Subpopulations and Circulating Myeloid-Derived Suppressor Cells as
Predictive Biomarkers in Advanced non-small Cell Lung Cancer Treated with ICIs
Federica Biello, AOU Maggiore della Carità di Novara, Novara, Italy

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 355P - EFFECT OF IMMUNOTHERAPY ON THE PERIPHERAL IMMUNOSCORE OF PATIENTS
AFFECTED BY NON-SMALL CELL LUNG CANCER LONG RESPONDERS OR FAST
PROGRESSORS
Niccolò Alessio, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

13:00 - 13:00 356P - DDR2 inhibition reveals a T cell immune checkpoint that controls lung cancer
immunosurveillance
Shuai Zhang, HUST - Huazhong University of Science and Technology, Wuhan, China

13:00 - 13:00 357P - Association of TROP2 quantitative continuous scoring (QCS) normalised membrane
ratio (NMR) with efficacy in Chinese patients (pts) with advanced/metastatic non-small
cell lung cancer (a/mNSCLC) treated with datopotamab deruxtecan (Dato-DXd) in
TROPION-PanTumor02
Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital &
Guangdong Academy of Medical Sciences, Guangzhou, China

13:00 - 13:00 358P - Baseline circulating immunophenotype may predict irAEs onset in NSCLC patients
treated with ICIs.
Alessandra Dodi, University Hospital of Parma, Parma, Italy

13:00 - 13:00 359P - Prognostic role of B7H3 in non-small cell lung cancer patients treated with immune
checkpoint inhibitors
Xinxin Zhi, Shanghai Pulmonary Hospital, Shanghai, China

13:00 - 13:00 360P - Lymphocyte Activation Gene-3 (LAG-3) and Cluster of Differentiation-155 (CD-155)
expression by immunohistochemistry do not predict response and survival in non-small
lung cancer (NSCLC) patients treated with second-line nivolumab treatment
Aslihan Apaydin Rollas, Hacettepe University - Faculty of Medicine, Ankara, Türkiye

13:00 - 13:00 361P - MICROBIOTA BIOMARKERS AS PREDICTORS OF IMMUNOTHERAPY RESPONSE IN

PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
Juan Vicente-Valor, UCM - Universidad Complutense de Madrid, Madrid, Spain

13:00 - 13:00 362P - LIPI score in advanced NSCLC treated with ICIs: prognostic impact and blood
immune-inflammatory correlations
Martina Manini, University of Parma, Parma, Italy

13:00 - 13:00 363P - Retrospective evaluation of biomarkers (KRAS, TP53, STK11, KEAP1, POLE, PIK3CA
and ARID1A) in pts with mNSCLC undergoing ICI mono or in combination with
chemotherapy
Julia Roeper, Pius Hospital, Oldenburg, Germany

13:00 - 13:00 364P - Relationship of LIPI index and C-reactive protein with survival in a cohort of
patients with advanced non-small cell lung carcinoma (NSCLC) treated with
immunotherapy
Raquel Manjon Gomez, Hospital Universitario Badajoz (Hospital Infanta Cristina), Badajoz, Spain

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 365P - Association of TP53 Mutation in Liquid Biopsy with Clinical Characteristics and
Prognosis in Metastatic Non-Small Cell Lung Cancer (NSCLC)
José Fuentes Pradera, Hospital Universitario Virgen de Valme, Seville, Spain

13:00 - 13:00 366P - Tumor derived exosomes in mediating cross-talk between PBMCs and EGFR mutant
NSCLC cells and their role in osimertinib resistance.
Luisa Amato, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy

13:00 - 13:00 367P - Clinical Characteristics and ctDNA as Prognostic Tools in KRAS-Mutated NSCLC
During First line treatment (1L)
Paula Espinosa Olarte, University Hospital 12 De Octubre, Madrid, Spain

13:00 - 13:00 368P - Molecular diagnosis of lung cancer via ctDNA and ctRNA detection on bronchoscopic
fluid: a bicenter prospective study (BiLiBro)
Gabrielle Danino, Hopital Tenon AP-HP, Paris, France

13:00 - 13:00 369P - Biological correlates of cell free DNA (cfDNA) Tumor Fraction (TF) in advanced
NSCLC.
Filippo Dall'Olio, Institut Gustave Roussy, Villejuif, France

13:00 - 13:00 370P - Transcriptome Data-Based Prognosis Prediction Model for Lung Adenocarcinoma
Using an Image Deep Learning Approach
Hsuanyu Chen, Academia Sinica, Taipei City, Taiwan

13:00 - 13:00 371P - Lung.cregmap: a web application to explore lung cancer heterogeneity through its
coregulation network.
Geoffrey Pawlak, University of Lille, Lille, France

13:00 - 13:00 372P - Sympathetic Signals Promote Immunosuppressive Neutrophils for Tumor
Progression in the Lung
Ruoyi Jin, Peking University People's Hospital, Beijing, China

13:00 - 13:00 373P - Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival
outcomes and immune-inflammatory profiles in patients with advanced NSCLC
undergoing chemo-immunotherapy
Giulia Mazzaschi, University Hospital of Parma, Parma, Italy

13:00 - 13:00 374P - Prognostic relevance of post-cycle 1 pembrolizumab levels in Real-world NSCLC
patients receiving first line IO or ChIO
Cristina Martinez, Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta
De Hierro Majadahonda, Majadahonda, Spain

13:00 - 13:00 375P - Multi-Omics Revealed Unique Metabolic Resistance Mechanisms to Third-
Generation EGFR-TKI in EGFR-Mutant Non-Small Cell Lung Cancer
Ruyun Gao, Chinese Academy of Medical Sciences and Peking Union Medical College - National
Cancer Center, Beijing, China

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 376P - Crosstalk Between CAFs and Cancer Cells is mediated by hMENA-regulated
secretory autophagy and affects immunotherapy response in NSCLC
Annalisa Tocci, IRCCS Regina Elena National Cancer Institute, Roma, Italy

13:00 - 13:00 377P - In Silico Exploration of Furin-Heparin Interactions and GNPDA1 Inhibitor
Development for Glycosylation in NSCLC
Rodrigo Ferreira, University of Brasilia - Health Sciences College, Brasilia, Brazil

13:00 - 13:00 378P - LncRNA RP11-888D10.4 expression upregulates invasion and metastasis through
epithelial-mesenchymal transition in lung cancer cells
Jung-Jyh Hung, National Yang Ming Chiao Tung University, Taipei, Taiwan

13:00 - 13:00 379P - Precursor T-cell Exhaustion Characterizes Improved Survival in Non-
Immunotherapy Treated Oligometastatic Lung Adenocarcinoma with Brain Metastases
Raphael Werner, USZ - University Hospital Zürich, Zurich, Switzerland

13:00 - 13:00 380P - RRAS and RRAS2 hotspot mutations as novel actionable oncogenic drivers in lung
adenocarcinoma
Marc Ladanyi, Memorial Sloan Kettering Cancer Center, New York, United States of America

13:00 - 13:00 381P - Empowering Global Oncology: DBS-TARGET Enables High-Sensitivity Mutation
Detection Anywhere
Liu Jingjing, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei City, Anhui
Province, China

13:00 - 13:00 382P - Unveiling DEFB1 as a Novel Driver and Promising Therapeutic Target in Lung
Adenocarcinoma
Cheng Zhan, Fudan University, Shanghai, China

13:00 - 13:00 383P - KRAS G12C vs. non-G12C non-small cell lung cancer (NSCLC): insights from gene
expression analysis
Laura Masfarre Pinto, Hospital del Mar-CIBERONC, Barcelona, Spain

13:00 - 13:00 384P - The Role of LYCAT in EGFR-TKI Resistance, NSCLC Progression, and Smoking-Induced
Lung Cancer
Stephanie Lopez, University of Illinois College of Medicine, Peoria, United States of America

13:00 - 13:00 385P - KRAS-dependent and independent impact of STK11 mutations in NSCLC: Clinical
characteristics
Nele Wagener, University Hospital Cologne, Cologne, Germany

13:00 - 13:00 386P - Comparison between CSF circulating tumor DNA, cytology and imaging for
diagnosis of leptomeningeal metastases in non-small cell lung cancer: a retrospective
study
Joyce Leung, Chinese CHUK - University of Hong Kong, Sha Tin, Hong Kong SAR, China

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 387P - Machine learning-assisted metabolomics for development model of predicting 1-
year overall survival in lung cancer patients with malignant pleural effusion
Wang Sufei, Union Hospital, Tongji Medical College, Huazhong University of Science and
Technology, Wuhan, China

13:00 - 13:00 388P - Adenox: A Machine Learning Model to Predict Molecular Targets in Non-Small Cell
Lung Cancer
Melike Comert, Bezmialem Vakif University Hospital, Istanbul, Türkiye

13:00 - 13:00 389P - Predicting Drug Response and Progression-Free Survival Using Patient-Derived
Lung Cancer Organoid-Based Diagnostic Response Prediction (CODRP)
Seung Joon Kim, The Catholic University of Korea - Seoul St. Mary's Hospital - Catholic Medical
Center, Seoul, Republic of Korea

13:00 - 13:00 390P - Evaluate the effects of VMAT and IMRT treatment techniques on critical organs with
different treatment planning algorithms
Ayça Ça?Lan, Gulhane Training and Reseach Hospital, Ankara, Türkiye

13:00 - 13:00 391P - Melatonin as a Radioprotective Agent: Assessing Its Efficacy in Preventing Lung
Injury Induced by Radiation Therapy
Hidayet Dincbas, Istanbul University - Cerrahpasa Faculty of Medicine, Istanbul, Türkiye

13:00 - 13:00 392P - Integrating Wearable Devices and Electronic Patient Reported Outcomes for
Continuous Perioperative Monitoring: Novel Evidence for Enhanced Recovery after
Thoracic Surgery
Runchen Wang, Guangzhou Medical University, Guangzhou, China

13:00 - 13:00 393P - Narciclasine as a novel treatment for lung cancer and malignant pleural
mesothelioma: insights from 3D tumor spheroid models.
Veronique Serre-Beinier, HUG - Hopitaux Universitaires de Geneve, Geneva, Switzerland

13:00 - 13:00 394P - Advancing lung cancer chemotherapy via single-lung perfusion and blood flow
occlusion
Erik Claes, University of Antwerp, Antwerpen, Belgium

13:00 - 13:00 395P - H3K27Me3-nucleosome is a strong Prognostic Biomarker in Non-Small Cell Lung
Cancer (NSCLC): interim results from the analysis of up to 1050 samples at baseline
Marie Piecyk, CICLY - Centre pour l'lnnovation en Cancérologie de Lyon - Université Lyon 1-EA
3738, Oullins, France

13:00 - 13:00 396P - Patient-derived tumoroid xenograft models for preclinical validation of
therapeutics for pleural mesothelioma
Raphael Werner, USZ - University Hospital Zürich, Zurich, Switzerland

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 397P - Comparison of Different Dose Accumulation Techniques to Determine Out-of-Field
Accuracy for Multiple Lesions in Lung SBRT
Esil Kara, Etlik City Hospital, Ankara, Türkiye

13:00 - 13:00 398P - The roles of ‘Quinacrine’ (QC) in cell migration and angiogenesis are
pivotal to the metastatic spread of human lung cancer cells cultured in vitro and
xenograft mouse models.
Angshuman Sarkar, BITS Pilani, K. K. Birla - Goa Campus, Zuarinagar, India

13:00 - 13:00 399P - Microplastic Exposure in COPD Alters the Immune Microenvironment: Implications
for Tumor-Promoting Inflammation
Wangrui Liu, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
Shanghai, China

13:00 - 13:00 400TiP - PYNNACLE Phase 2 assessing rezatapopt in patients with advanced solid tumors,
including lung cancer, harboring a TP53 Y220C mutation
María Jose De Miguel, CIOCC - Centro Integral Oncológico Clara Campal, Hospital Universitario
HM Sanchinarro, Madrid, Spain

13:00 - 13:00 401P - Access to molecular testing for lung cancer in France: a national cross-sectional
survey of routine practices
Arnaud Bayle, Institut Gustave Roussy, Villejuif, France

13:00 - 13:00 402P - Tumor suppressor genes (TSG) in NSCLC with gene fusions
Lorenza Landi, IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, Italy

13:00 - 13:00 403P - Higher predilection of driver mutation positive Squamous Lung Cancer in the Asia
Pacific region
Sewanti Limaye, SIR H N RELIANCE FOUNDATION HOSPITAL, MUMBAI, India

13:00 - 13:00 404P - The 41BB agonist potentiates the therapeutic efficacy of irreversible electroporation
combined with immune adjuvants for lung cancer by promoting not only tissue-resident
memory CD8 + T cell but also cDC1 responses
Yu Feng, Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China

13:00 - 13:00 405P - Targeting AURKA, nuclear factor erythroid-2-related factor 2 (Nrf2), and
phosphoserine aminotransferase 1 (PSAT1) in KRASG12C-mutant lung adenocarcinoma
Mengxin Zhou, IOR - Instituto Oncologico Dr. Rosell, Barcelona, Spain

13:00 - 13:00 406P - Rescuing treatment-induced epigenetic alterations in cancer-associated fibroblasts

as a potential chemo-sensitization strategy in stroma-rick tumors
Kelvin Tsai, TMU - Taipei Medical University, Taipei City, Taiwan

13:00 - 13:00 407P - Dissecting clinicopathologic features and treatment response in patients with
LKB1-inactive NSCLC
Giorgia Di Liberti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 408P - Real-life Experience of Rare Hepatoid Adenocarcinomas of the Lung : A Large
Retrospective French Cohort
Thomas Favé, CHRU Brest - Hopital Augustin Morvan, Brest, France

13:00 - 13:00 409P - IMpower010: Digital pathology (DP) vs manual SP263 PD-L1 tumour cell (TC) scoring
on whole imaging slides from patients (pts) with stage II-IIIA PD-L1 TC _50% NSCLC
Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for
Lung Research, Grosshansdorf, Germany

13:00 - 13:00 410P - Cetuximab enhances cytotoxicity of fulzerasib and sotorasib in KRAS-mutant lung
cancer
Daniel Olmo González, FIOR group. Dexeus University Hospital, Barcelona, Spain

13:00 - 13:00 411P - Tumor miRNAs in small-extracellular vesicles dampen the CD8+ T cell response
against tumor and predict response to immunotherapy in NSCLC.
Elvire Pons-Tostivint, CHU du Nantes - Hôtel-Dieu, Nantes, France

13:00 - 13:00 412P - Re-GraDE NSCLC: First real-world data on the daily practice of pathologic response
assessment following Immune oncologic combination therapies in NSCLC in Germany
Felix Elsner, Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU),
Erlangen, Germany

13:00 - 13:00 413P - Classifying Multiple Lung Cancers by Spatial Microenvironment: Tertiary Lymphoid
Structures at Interface Zone as Immune Hubs and Prognostic Determinants
Xiaoqiu Yuan, Peking University People's Hospital, Beijing, China

13:00 - 13:00 414P - Exosome Whisperers: Decoding SPHK1's Role in Cisplatin-induced immune escape
of NSCLC
Huan Gao, the first affiliated hospital of xi'an jiaotong university, Xi’an, China

13:00 - 13:00 415P - Transformer-based AI approach to unravel long-term, time-dependent prognostic

complexity in patients with advanced NSCLC and PD-L1 _50%: insights from the
Pembrolizumab 5-year global registry
Alessio Cortellini, Policlinico Universitario Campus Bio-Medico, Rome, Italy

13:00 - 13:00 416P - Application of Artificial Intelligence: Machine Learning for Survival Prediction in
Non-Small Cell Lung Cancer with Brain Metastases
Julia Giner, Hospital de Sabadell Corporacis Parc Tauli, Sabadell, Spain

13:00 - 13:00 417P - Deep Neural Networks Prognosis for Lung Cancer with Non-Omics Data: African
Cohort
Hassan Abdelilah Tafenzi, Cadi Ayad University - Faculty of Medicine and Pharmacy - CHU
Mohamed-VI, Marrakech, Morocco

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 418P - Low fT3/fT4 Ratio as a Proxy for Muscle Wasting in Patients with Advanced Non-
Small Cell Lung Cancer Treated with First-Line Pembrolizumab: A Metabolic Multi-Omic
Analysis
Lorenzo Belluomini, AOU Integrata di Verona - Ospedale Borgo Roma, Verona, Italy

13:00 - 13:00 419P - Predictors and outcomes of non-small cell lung carcinoma (NSCLC) patients
following severe immune checkpoint inhibitor (ICI) toxicity: A real-world UK multi-centre
study.
Umair Mahmood, Churchill Hospital, Oxford, United Kingdom

13:00 - 13:00 420P - Predictive value of inflammatory scores for the development of clinical
complications in lung cancer - a prospective study by the European Lung Cancer Working
Party (ELCWP)
Ilann Oueslati, ULB - Université Libre de Bruxelles, Brussels, Belgium

13:00 - 13:00 421P - ANTIBIOTIC PRESCRIPTION PATTERNS AND THEIR ASSOCIATION WITH OUTCOMES
IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (aNSCLC) TREATED WITH
IMMUNE CHECKPOINT INHIBITORS (ICI)
Lea Knez, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia

13:00 - 13:00 422P - Acute Pneumonitis in Patients Receiving Thoracic Radiotherapy and Pre-Treated
with Immune Checkpoint Inhibitors
Federico Colombo, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

13:00 - 13:00 423P - Toxicity and Survival Following Lung Radiotherapy in Patients with Interstitial Lung
Abnormalities and Interstitial Lung Disease
Sarah Bowen Jones, The Christie NHS Foundation Trust, Manchester, United Kingdom

13:00 - 13:00 424P - Real World Data of lenvatinib in patients with Thymic epithelial tumors (TETs)
Álvaro López Gutiérrez, University Hospital of Salamanca, Salamanca, Spain

13:00 - 13:00 425P - Real World Data of everolimus in patients with Thymic epithelial tumors (TETs)
Álvaro López Gutiérrez, University Hospital of Salamanca, Salamanca, Spain

13:00 - 13:00 426P - Ototoxicity and Safety Profile of Capmatinib in NSCLC: Insights from Real-World
FAERS Data (2020-2023)
Siqi Xu, Clinical Oncology School of Fujian Medical University, Fuzhou, China

13:00 - 13:00 427P - Postmarketing safety of anaplastic lymphoma kinase inhibitors: an analysis of
selected adverse events in the EudraVigilance database
Lea Knez, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia

13:00 - 13:00 428P - Real-World Effectiveness and Cost-Utility Analysis of Second-Line Immunotherapy
for Non-Oncogene-Addicted Advanced Non-Small Cell Lung Cancer
Sasiporn Sawasdisara, Mahidol University - Faculty of Medicine - Siriraj Hospital, Bangkok,
Thailand

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 429P - Real-world versus pathology panel-reviewed treatment outcomes in patients with
stage IV LCNEC: a nationwide registry study
Frank Heijboer, Erasmus MC, Rotterdam, Netherlands

13:00 - 13:00 430P - Privacy-Preserving LLMs for Automated Clinical Feature Extraction: A Real-World
Study in NSCLC EGFR-Mutated patients
Laura Mazzeo, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

13:00 - 13:00 431P - Molecular Testing Practices for Lung Cancer: Survey Insights from South Korean
Pathology Laboratories
Sehui Kim, Korea University Guro Hospital, Seoul, Republic of Korea

13:00 - 13:00 432P - Real-World Biomarker Testing and Treatment Patterns in Belgian Lung Cancer
Patients: Insights from the AIBED Study
Lore Decoster, UZ Brussel - Universitair Ziekenhuis Brussel, Jette, Belgium

13:00 - 13:00 433P - Clinical characterization of tracheal and pulmonary adenoid cystic carcinoma: A
French Institutional Experience
E Sais, ICO Girona - Institut Català d'Oncologia Girona, Girona, Spain

13:00 - 13:00 434P - Clinicopathological Characteristics and Aggressive behavior of SMARCA4-Deficient

undifferentiated thoracic tumors mimicking NSCLC: Data from a tertiary cancer center in
India
Nivedita Patnaik, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

13:00 - 13:00 435P - Inequities in anticancer drug access in neighboring countries in East Central and
South-East Europe for the treatment of non-small cell lung cancer (NSCLC) patients
Urska Janzic, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia

13:00 - 13:00 436P - Demographics, Clinical Characteristics and Treatment of Lung Cancer in a
Developing Country: A Pilot Study in Malaysia
Wen Xuan Lee, Sunway University, Bandar Sunway, Malaysia

13:00 - 13:00 437P - Evaluating Clinico-Radiological Models in Pulmonary Nodule Outcomes: Lessons
from a Retrospective Analysis of MDT-Based Decisions
Zaw Aung, Glenfield Hospital - University Hospitals of Leicester NHS Trust, Leicester, United
Kingdom

13:00 - 13:00 438P - Clinical trials in thoracic oncology: where do we come from, and where are we now?
Benoît Allignet, Centre Léon Bérard, Lyon, France

13:00 - 13:00 439P - Standardization of endpoints in early NSCLC randomized clinical trials (RCTs): the
DATECAN initiative
Priscilla Cascetta, Institut Gustave Roussy, Villejuif, France

Last update: 05-03-2025 10:21:13am

 13:00 - 13:00 440P - Sexual Health and its Impact on Quality of Life of Patients with Lung Cancer
Mafalda Da Costa, ULS Matosinhos - Hospital Pedro Hispano EPE - SNS, Senhora da Hora,
Portugal

13:00 - 13:00 441P - HOPE FOR OOPE : Beyond TKI's in Treatment of NSCLC
Pathi Nikhil, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad,
India

13:00 - 13:00 Test poster print Test

Sonja Kreil, CTI Meeting Technology, Vienna, Austria

14:00 - 14:30 Type: Keynote lecture Room South Paris

Title: Less is more: De-escalation strategies in patient management and
clinical trials
Moderation: Myung-Ju Ahn, Republic of Korea

14:00 - 14:05 Introduction

Myung-Ju Ahn, Samsung Medical Center - Sungkyunkwan University School of Medicine, Seoul,
Republic of Korea

14:05 - 14:30 Less is more: De-escalation strategies in patient management and clinical trials
Benjamin Besse, Institut Gustave Roussy, Villejuif, France

14:45 - 16:15 Type: Young Oncologists session Room N03

Title: YO Clinical cases discussion
Moderation: Elene Mariamidze, Georgia; Myrto Moutafi, Greece; Hongcheng Zhu, China

14:45 - 14:48 Introduction

Myrto Moutafi, Attikon University Hospital, Haidari, Greece

14:48 - 14:58 Clinical case 1 - A Deceptive victory: A complete response that hid another battle
Yago Garitaonaindía Díaz, Majadahonda, Spain

14:58 - 15:08 Expert discussion of clinical case 1

Isabelle Opitz, Zurich, Switzerland

15:08 - 15:18 Clinical case 2 - A case of oligometastatic small cell lung cancer
Sevinc Balli, Ankara, Türkiye

15:18 - 15:28 Expert discussion of clinical case 2

Fiona Mcdonald, The Royal Marsden Hospital - Chelsea, London, United Kingdom

15:28 - 15:38 Clinical case 3 - Challenges and pitfalls in the treatment of locally advanced RET-fusion
positive NSCLC
Rita Leporati, Modena University Hospital, Modena, Italy, Modena, Italy

Last update: 05-03-2025 10:21:13am

 15:38 - 15:48 Expert discussion of clinical case 3
Jordi Remon Masip, Institut Gustave Roussy, Villejuif, France

15:48 - 16:15 Q&A and discussion

Elene Mariamidze, Todua Clinic, Tbilisi, Georgia

14:45 - 16:15 Type: Patient Advocacy session Room W03

Title: From screening to survivorship: Building a comprehensive lung
cancer continuum of care
Moderation: Anne-Marie Baird, Ireland; Jill Feldman, United States of America

14:45 - 15:05 Improving screening in high-risk populations: A path to health equity

David R. Baldwin, Nottingham City Hospital, Nottingham, United Kingdom

15:05 - 15:25 From patient to survivor: Navigating the post-treatment journey in lung cancer
Jill Feldman, EGFR Resisters, Deerfield, United States of America

15:25 - 15:45 Addressing the long-term needs of lung cancer survivors

Merel Hennink, Longkanker Nederland, Utrecht, Netherlands

15:45 - 16:05 Insights and innovations: Lessons learned from lung cancer screening programmes
Carlijn Michelle Van Der Aalst, Erasmus MC - University Medical Center, Rotterdam, Netherlands

16:05 - 16:15 Q&A and discussion

14:45 - 16:15 Type: Educational session Room N02

Title: Treatment challenges in the light of the 9th edition TNM
Moderation: Hisao Asamura, Japan; Paula Ugalde, United States of America

14:45 - 15:05 The need for precision staging in view of the N2a and N2b categories
Sergi Call, Hospital Mutua de Terrassa, Terrassa, Spain

15:05 - 15:25 N2a and N2b: Opportunities for new therapeutic strategies
Raymond Osarogiagbon, Baptist Memorial Hospital, Memphis, United States of America

15:25 - 15:45 M1c1 and M1c2: Does anatomic extent really matters in the light of targeted therapies and
immunotherapy?
Jarushka Naidoo, Beaumont Hospital, Dublin, Ireland

15:45 - 16:05 Why we need yp-stages in future editions of the TNM classification?
Hisao Asamura, Keio University School of Medicine, Shinjuku-ku, Japan

16:05 - 16:15 Q&A and discussion

Last update: 05-03-2025 10:21:13am

 14:45 - 16:15 Type: Proffered Paper session Room South Paris
Title: Proffered Paper session 2

14:45 - 14:55 LBA4 - Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with
unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC):
Updated overall survival (OS) analysis from the LAURA study
Suresh Ramalingam, Winship Cancer Institute of Emory University Atlanta, Atlanta, United States
of America

14:55 - 15:05 186O - Pembrolizumab (Pembro) Plus Concurrent Chemoradiation Therapy (cCRT) in
Unresectable Locally Advanced Non-Small-Cell Lung Cancer (NSCLC): Final Analysis of
KEYNOTE-799
Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for
Lung Research, Grosshansdorf, Germany

15:05 - 15:15 Invited discussant LBA4 and 186O

Sara Ramella, Policlinico Universitario Campus Bio-Medico, Rome, Italy

15:15 - 15:25 Q&A and discussion

15:25 - 15:35 187O - A Multifactorial Score to Predict Surgical Complexity of Lung Resection Following
Neoadjuvant Chemo-Immunotherapy
Marco Nardini, Leeds Cancer Centre, Leeds, United Kingdom

15:35 - 15:45 LBA3 - Sites of relapse and subsequent therapy in the BR.31 phase 3 study of durvalumab
vs placebo in resected stage IB-IIIA NSCLC
Virginie Westeel, CHRU Besancon - Hopital Jean Minjoz, Besancon, France

15:45 - 15:55 188O - Patient-reported outcomes (PROs) with perioperative durvalumab in resectable
NSCLC (AEGEAN)
Giulia Pasello, University of Padua/Istituto Oncologico Veneto IRCCS, Padova, Italy

15:55 - 16:05 Invited Discussant 187O, LBA3 and 188O

Jonathan Spicer, McGill University, Montreal, Canada

16:05 - 16:15 Q&A and discussion

16:15 - 16:45 Type: Coffee break Foyer

Title: Coffee break

16:45 - 17:45 Type: Industry Satellite Symposium Room N03

Title: Accord Healthcare - Expanding treatment options in extensive-stage
small cell lung cancer
Moderation: Thomas Newsom-Davis, United Kingdom

16:45 - 16:55 Welcome and introduction

Thomas Newsom-Davis, Chelsea and Westminster Hospital - NHS Trust, London, United Kingdom

Last update: 05-03-2025 10:21:13am

 16:55 - 17:15 Emerging chemo-immunotherapy data in first-line treatment of ES-SCLC
Francesco Grossi, University of Insubria, Varese, Italy

17:15 - 17:35 Navigating approaches to second-line treatment of ES-SCLC

Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for
Lung Research, Grosshansdorf, Germany

17:35 - 17:45 Q&A, concluding remarks

Thomas Newsom-Davis, Chelsea and Westminster Hospital - NHS Trust, London, United Kingdom

16:45 - 17:45 Type: Industry Satellite Symposium Room N02

Title: Pfizer - Promising new targets and ADCs in development for NSCLC
Moderation: David Planchard, France; Anna Minchom, United Kingdom

16:45 - 16:50 Welcome and Introduction

David Planchard, Institut Gustave Roussy, Villejuif, France

16:50 - 17:10 “Are we making progress? Updates on late-stage ADCs in NSCLC

David Planchard, Institut Gustave Roussy, Villejuif, France

17:10 - 17:30 What’s next in NSCLC? New targets and ADC innovations
Anna Minchom, Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research,
Sutton, United Kingdom

17:30 - 17:45 Conclusions and panel discussion

David Planchard1, Anna Minchom2, 1Institut Gustave Roussy, Villejuif, France, 2Drug
Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, United Kingdom

Last update: 05-03-2025 10:21:13am

 29.03.2025
08:15 - 09:45 Type: Educational session Room N02
Title: IO in early stage NSCLC
Moderation: Andrea Riccardo Filippi, Italy; Jarushka Naidoo, Ireland

08:15 - 08:35 Is time to definitive deterioration in quality of life the new key endpoint for early-stage
NSCLC?
Cecilia Pompili, University of Leeds - Institute of Cancer and Pathology (LICAP), Leeds, United
Kingdom

08:35 - 08:55 SBRT + IO: The new standard?

Andrea Riccardo Filippi, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

08:55 - 09:15 Achieve high quality care with emerging evidence in early-stage NSCLC in diverse health
care settings
Boris Sepesi, Sarah Cannon Research Institute (SCRI) at HealthONE, Denver, United States of
America

09:15 - 09:35 Surgical conduct in the age of IO across the spectrum of complexity
Sarah Najmeh, McGill University, Montreal, Canada

09:35 - 09:45 Q&A and discussion

08:45 - 09:45 Type: Multidisciplinary Tumour Board Room N03

Title: Optimal treatment approaches for CNS metastasis
Moderation: Michael Weller, Switzerland; Myung-Ju Ahn, Republic of Korea

08:45 - 08:55 Case presentation

Angela Botticella, Gustave Roussy - Cancer Campus, Villejuif, France

08:55 - 09:10 The role of stereotactic radiotherapy

Michael Weller, USZ - Universitätsspital Zürich - Klinik für Neurologie, Zurich, Switzerland

09:10 - 09:25 The role of systemic therapy

Sarah Goldberg, Yale University School of Medicine - Yale Cancer Center, New Haven, United
States of America

09:25 - 09:45 Q&A and discussion

09:45 - 10:10 Type: Coffee break Foyer

Title: Coffee break

10:10 - 11:40 Type: Educational session Room N03

Title: Adressing resistance in NSCLC: Precision medicine approaches
Moderation: Laura Mezquita, Spain; Roberto Ferrara, Italy

Last update: 05-03-2025 10:21:13am

 10:10 - 10:30 Understanding the mechanism of resistance to targeted therapies in NSCLC
Sandra Ortiz-Cuaran, Centre Léon Bérard, Lyon, France

10:30 - 10:50 Will resistance guide the sequential treatment strategy in lung cancer?
Laura Mezquita, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain

10:50 - 11:10 Innovations to overcome targeted therapy resistance: From bench to bedside
Luc Friboulet, Gustave Roussy - Cancer Campus, Villejuif, France

11:10 - 11:30 Overcoming primary resistance to immunotherapy

Roberto Ferrara, UniSR - Università Vita e Salute San Raffaele Milano, Milan, Italy

11:30 - 11:40 Q&A and discussion

10:10 - 11:40 Type: Educational session Room N02

Title: Next generation ADCs
Moderation: Lizza Hendriks, Netherlands; Benjamin Besse, France

10:10 - 10:30 ADC in wild type advanced NSCLC

Lizza Hendriks, Maastricht University Medical Center (MUMC), Maastricht, Netherlands

10:30 - 10:50 ADC in oncogenic addicted NSCLC

Giannis Mountzios, Henry Dunant Hospital Center, Athens, Greece

10:50 - 11:10 Current challenges with ADC in NSCLC

Noemi Reguart, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain

11:10 - 11:30 Mechanisms of resistance of ADC

Sarat Chandarlapaty, MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States
of America

11:30 - 11:40 Q&A and discussion

11:45 - 12:30 Type: ELCC Takeaways Room N02

Title: ELCC 2025:Takeaways
Moderation: Enrico Ruffini, Italy; Myung-Ju Ahn, Republic of Korea

11:45 - 12:00 Radiation oncology

Rafal Dziadziuszko, Medical University of Gdansk, Gdansk, Poland

Last update: 05-03-2025 10:21:13am

 12:00 - 12:15 Surgery
Jonathan Spicer, McGill University, Montreal, Canada

12:15 - 12:30 Medical oncology

Noemi Reguart, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain

Last update: 05-03-2025 10:21:13am